US9687456B2 - Nutritional compositions for modulating inflammation including exogenous vitamin K2 - Google Patents

Nutritional compositions for modulating inflammation including exogenous vitamin K2 Download PDF

Info

Publication number
US9687456B2
US9687456B2 US15/099,257 US201615099257A US9687456B2 US 9687456 B2 US9687456 B2 US 9687456B2 US 201615099257 A US201615099257 A US 201615099257A US 9687456 B2 US9687456 B2 US 9687456B2
Authority
US
United States
Prior art keywords
vitamin
inflammation
bone
nutritional composition
exogenous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US15/099,257
Other versions
US20160220511A1 (en
Inventor
Douglas Richard Bolster
Zamzam Kabiry Roughead
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec SA filed Critical Nestec SA
Priority to US15/099,257 priority Critical patent/US9687456B2/en
Publication of US20160220511A1 publication Critical patent/US20160220511A1/en
Assigned to NESTEC S.A. reassignment NESTEC S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BOLSTER, DOUGLAS RICHARD, ROUGHEAD, ZAMZAM KABIRY
Priority to US15/389,945 priority patent/US20170105948A1/en
Application granted granted Critical
Publication of US9687456B2 publication Critical patent/US9687456B2/en
Assigned to Société des Produits Nestlé S.A. reassignment Société des Produits Nestlé S.A. MERGER (SEE DOCUMENT FOR DETAILS). Assignors: NESTEC S.A.
Assigned to Société des Produits Nestlé S.A. reassignment Société des Produits Nestlé S.A. CORRECTIVE ASSIGNMENT TO CORRECT THE ENGLISH TRANSLATION TO SHOW THE FULL AND CORRECT NEW NAME IN SECTION 51. PREVIOUSLY RECORDED AT REEL: 049391 FRAME: 0756. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER. Assignors: NESTEC S.A.
Assigned to Société des Produits Nestlé S.A. reassignment Société des Produits Nestlé S.A. CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Assignors: NESTEC S.A.
Assigned to Société des Produits Nestlé S.A. reassignment Société des Produits Nestlé S.A. CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Assignors: NESTEC S.A.
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/306—Foods, ingredients or supplements having a functional effect on health having an effect on bone mass, e.g. osteoporosis prevention
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/15—Inorganic Compounds
    • A23V2250/156—Mineral combination
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/70—Vitamins
    • A23V2250/714—Vitamin K
    • A23V2250/7144—Vitamin K2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Definitions

  • the present disclosure generally relates to health and nutrition. More specifically, the present disclosure relates to nutritional compositions including exogenous vitamin K2 and methods of making and using the nutritional compositions.
  • Nutritional compositions can be targeted toward certain consumer types, for example, young, elderly, athletic, etc., based on the specific ingredients of the nutritional composition.
  • Nutritional compositions can also be formulated based on the certain physiological conditions that the nutritional compositions are intended to treat or improve.
  • One goal of nutritional support is to improve bone health by increasing bone density and strength and reducing the incidence of fracture risk. Due to rapidly changing bone densities in children during normal growth and development, or due to underlying medical conditions, children may require nutritional compositions to improve indices of bone health and promote bone growth and bone quality.
  • Nutritional compositions having exogenous vitamin K2 and methods of making and using the nutritional compositions are provided.
  • the present disclosure provides a nutritional composition including exogenous K2.
  • the nutritional composition can be a complete nutritional or as an oral nutritional supplement (incomplete nutritional).
  • the nutritional composition can be in a formulation designed for any mammal such as a human or an animal.
  • the active ingredients in the nutritional composition can also be provided as a modular product.
  • a modular product can be defined as a method of delivering one or more specific nutrients as a supplement and not intended to be used for sole source nutrition.
  • the nutritional composition further includes one or more prebiotics.
  • the prebiotic can be fructooligosaccharides, inulin, lactulose, galactooligosaccharides, acacia gum, soyoligosaccharides, xylooligosaccharides, isomaltooligosaccharides, gentiooligosaccharides, lactosucrose, glucooligosaccharides, pecticoligosaccharides, guar gum, partially hydrolyzed guar gum, sugar alcohols, alpha glucan, beta glucan, or a combination thereof.
  • the nutritional composition further includes one or more probiotics.
  • the probiotic can be Saccharomyces, Debaromyces, Candida, Pichia, Torulopsis, Aspergillus, Rhizopus, Mucor, Penicillium, Bifidobacterium, Bacteroides, Clostridium, Fusobacterium, Melissococcus, Propionibacterium, Streptococcus, Enterococcus, Lactococcus, Staphylococcus, Peptostrepococcus, Bacillus, Pediococcus, Micrococcus, Leuconostoc, Weissella, Aerococcus, Oenococcus, Lactobacillus or a combination thereof.
  • the nutritional composition further includes one or more amino acids.
  • the amino acid can be Alanine, Arginine, Asparagine, Aspartate, Citrulline, Cysteine, Glutamate, Glutamine, Glycine, Histidine, Hydroxyproline, Hydroxyserine, Hydroxytyrosine, Hydroxylysine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Proline, Serine, Taurine, Threonine, Tryptophan, Tyrosine, Valine, HICA (Alpha-Hydroxyisocaproic Acid), HIVA (Alpha-Hydroxyisovaleric Acid), HIMVA (alpha-hydroxymethylvaleric acid) or a combination thereof.
  • the nutritional composition further includes one or more proteins.
  • the nutritional composition further includes one or more nucleotides.
  • the nutritional composition further includes one or more synbiotics, fish oils, nonmarine omega-3 fatty acid containing dietary fat sources, phytonutrients and/or antioxidants.
  • the antioxidants can be, for example, vitamin A, vitamin B 1 , vitamin B 6 , vitamin B 12 , vitamin C, vitamin D, vitamin E, carotenoids, selenium, flavonoids, Lactowolfberry, Goji (wolfberry), polyphenols, lycopene, lutein, lignan, coenzyme Q10 (“CoQ10”), hesperidine and glutathione.
  • the nutritional composition is in an administerable form such as pharmaceutical formulations, nutritional formulations, tube-feed formulations, dietary supplements, functional foods, beverage products or a combination thereof.
  • the present disclosure provides a method of making a nutritional composition.
  • the method comprises adding exogenous vitamin K 2 and a component selected from the group consisting of phosphorus, magnesium, calcium, vitamin D, osteopontin, or combinations thereof to a nutritional composition.
  • the present disclosure provides a method of making a nutritional composition.
  • the method comprises adding exogenous vitamin K 2 and a component selected from the group consisting of phosphorous, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, osteopontin or combinations thereof to a nutritional composition.
  • the present disclosure provides a method of improving bone health (i.e. growth, mineralization, microarchitecture, bone organic matrix constituents, density, elasticity and strength) in pediatric patients.
  • the method comprises administering to a child in need of same a nutritional composition including an effective amount of exogenous vitamin K 2 .
  • the nutritional composition may further include a component selected from the group consisting of phosphorous, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, osteopontin or combinations thereof.
  • the present disclosure provides a method of promoting bone growth and bone quality in a pediatric patient having an underlying medical condition.
  • the method comprises administering to a pediatric patient having an underlying medical condition a nutritional composition including an effective amount of exogenous vitamin K 2 .
  • the present disclosure provides a method of reducing the risk of bone fracture in a pediatric patient.
  • the method comprises administering to a pediatric patient at risk of bone fracture a nutritional composition including an effective amount of exogenous vitamin K 2 .
  • the present disclosure provides a method for improving skeletal muscle health (i.e. metabolic function, lean body mass and mobility).
  • the method comprises administering to a patient who can benefit from improved skeletal muscle health a nutritional composition including an effective amount of exogenous vitamin K 2 .
  • An advantage of the present disclosure is to provide an improved nutritional composition having exogenous vitamin K 2 .
  • Another advantage of the present disclosure is to provide a method of making an improved nutritional composition.
  • Yet another advantage of the present disclosure is to provide a nutritional composition that promotes bone health.
  • Another advantage of the present disclosure is to provide a nutritional composition that promote bone growth and bone quality in patients having underlying medical conditions.
  • Still another advantage of the present disclosure is to provide a nutritional composition that minimizes bone fracture risk.
  • Vitamin K denotes a group of lipophilic, hydrophobic and essential vitamins having a common chemical ring structure (napthoquinone).
  • the two most important forms of vitamin K are vitamin K 1 , a single compound known as phylloquinone or phytomenadione, and vitamin K 2 , a series of vitamers known as menaquinones or menatetrenones.
  • vitamin K 1 a single compound known as phylloquinone or phytomenadione
  • vitamin K 2 a series of vitamers known as menaquinones or menatetrenones.
  • There are also several synthetic forms of vitamin K including, for example, vitamins K 3 , K 4 and K 5 .
  • Vitamin K 1 is the major form of vitamin K in a normal diet and is synthesized by plants including, for example, certain plant oils such as canola and soybean and in green leafy vegetables such as spinach, swiss chard, broccoli, cabbage, cauliflower, kale, and brussels sprouts.
  • Vitamin K 2 is a group of compounds called menaquinones (“MK”) having side chains composed of a variable number of unsaturated isoprenoid residues generally designated as MK-n, where n specifies the number of isoprenoids.
  • MKs menaquinones
  • MK-7 is typically synthesized by animal organs and muscle, while MK-7 is typically synthesized by bacteria during fermentation. Accordingly, MK-7 is particularly abundant in fermented products including cheese, curd cheese and natto (fermented soybeans) and has a particularly long half-life when compared to vitamin K 1 .
  • the estimated average requirement for vitamin K in children ages 1 to 18 years in the United States is based upon median intakes of vitamin K for adults. These levels are designed to meet the vitamin K levels required for normal blood coagulation and not other vitamin K-dependent proteins such as osteocalcin.
  • the ratio of undercarboxylated (i.e., inactive) to carboxylated osteocalcin can be a surrogate marker for vitamin K status. Recent evidence suggests that children between the ages of 6 and 18 years of age have elevated levels of undercarboxylated osteocalcin relative to adults. Rather than attempting to increase the intake levels via higher vitamin K 1 intake, vitamin K 2 allows for administration of a more potent form of vitamin K without negatively impacting parameters of anticoagulation.
  • vitamin K 2 provides better absorption and more stable serum levels through a longer half-life.
  • the improved bioavailability of vitamin K 2 to extrahepatic tissue may also allow for a greater impact on bone health (i.e. mineralization, microarchitecture and strength) during normal growth and development. Therefore, vitamin K 2 provides for a more potent form of the vitamin in which its enhanced bioavailability can impact bone health during normal growth and development.
  • Such conditions may include, for example, developmental delay, failure-to-thrive, neuromuscular dysfunction, severe food allergy and inflammatory bowel disease (e.g., Crohns disease or ulcerative colitis).
  • IBD inflammatory bowel disease
  • Vitamin K is a cited nutrition deficiency in this population and its limited bioavailability may reduce osteocalcin carboxylation as well as reduce bone strength, bone mineralization and bone microarchitecture. Accordingly, children suffering from any of the above-mentioned medical conditions may benefit from a more effective dose of vitamin K.
  • Vitamin K2 allows for a more potent form of vitamin K without negatively impacting parameters of anticoagulation. Specifically, vitamin K2 provides better absorption and more stable serum levels through a longer half-life when compared to phylloquinones (vitamin K1). Improved bioavailability of vitamin K2 to extraheptic tissue may allow for a greater impact for improving musculoskeletal health in patients with inflammatory bowel disease (IBD) (Crohn's Disease and Colitis), especially pediatric patients. The incidence of low bone mass ranges from 30-50% in children with IBD.
  • IBD inflammatory bowel disease
  • Vitamin K is a cited nutrition deficiency in this population and its limited availability may reduce osteocalcin carboxylation as well as reduce bone strength, bone mineralization and bone micro-architecture.
  • a low vitamin K status may be a causative factor in Crohn's Disease-associated osteopenia.
  • the osteopenia and elevated rate of bone resorption noted in some Crohn's Disease patients is a multifactorial process and vitamin K deficiency is certainly only one factor in this process.
  • Low vitamin K levels can lead to an increase in the rate of bone resorption, without a compensatory increase in the rate of bone formation.
  • An increased rate of bone turnover is associated with an increased risk of bone loss in Crohn's Disease patients.
  • Vitamin K2 may serve as a critical micronutrient for optimizing bone regulation in this target population.
  • vitamin K 2 may also be effective for bone health in pediatric patients undergoing concurrent drug treatments including, for example, corticosteroids, bisphosphonates or anti-coagulative drugs.
  • pediatric patients undergoing biologic therapies or having conditions of gastrointestinal (“GI”) impairment including, for example, short bowel syndrome, ulcerative colitis, celiac disease, cystic fibrosis, renal dysfunction and androgen deficiency, gluten intolerance, Crohns disease or severe allergy, may also benefit from administration of nutritional compositions having exogenous vitamin K 2 .
  • GI gastrointestinal
  • Applicant has surprisingly found that administering exogenous vitamin K 2 as part of a nutritional formulation will improve osteocalcin carboxylation and improve indicies of bone health during normal growth and development in children. Additionally, vitamin K 2 supplementation can also promote bone growth and bone quality in pediatric patients with underlying medical conditions in which bone growth and bone quality may be compromised. As a result, Applicant has found that administration of exogenous vitamin K 2 increases bone density and improves bone tissue microarchitecture in pediatric patients, thereby reducing the incidence for fracture risk.
  • vitamin K 2 may be seen directly on bone quality such that this form of vitamin K modulates formation of proteins in the organic matrix of the bone involved in microarchitectural morphology, mineralization, density, elasticity and mechanical stiffness, as measured by peripheral quantitative computer tomography (“pQCT”) or Dual Energy X-ray absorptiometry (“DEXA”). Vitamin K 2 may also be effective for bone health in patients undergoing concurrent drug treatment.
  • pQCT peripheral quantitative computer tomography
  • DEXA Dual Energy X-ray absorptiometry
  • bone density is expressed as the relationship between bone mass (expressed as the degree of photon attenuation through the bone, or bone mineral content (BMC)) and the image of the bone on a film (i.e., the area) (expressed as BMC/cm 2 ).
  • BMC bone mineral content
  • pQCT is a procedure that evaluates peripheral bone in 3 dimensions (volumetric) and is commonly applied to the forearm or tibia.
  • a radiation source typically x-rays
  • a sensor revolve around the bone under examination, which is them reconstructed on the computer screen in a three-dimensional (3-D) image.
  • pQCT is an optimal technique for evaluating bone geometry even though sensitivity varies with the site under evaluation.
  • pQCT measures true bone density (volumetric mineral bone density) because it normalizes the bone mineral content derived not from the projected area but rather from the volume of the examined bone.
  • pQCT can also be used to calculate the SSI, an index of bone resistance to torsion. The index takes into account bone geometry and the bone's mineral characteristics. See, Geometry and bone density, Radetti, G., et al., Panminerva Med 2006; 48:181-6.
  • DEXA is based on x-ray spectrometry and it's fundamental principle is based on the degree of attenuation of x-rays emitted from 2 different sources of energy.
  • DEXA is normally used to evaluate lumbar or proximal femoral bone mineralization.
  • DEXA has an accuracy of 4-10% and a coefficient of variation of 1-1.5%. See, Id.
  • the present disclosure relates to nutritional compositions including exogenous K 2 and methods of making and using the nutritional compositions.
  • the present disclosure also relates to the use of pQCT and DEXA to measure bone density and bone tissue microarchitecture.
  • Embodiments of the nutritional compositions of the present disclosure can promote the increase of bone density, mineralization and mechanical stiffness as well as improved bone tissue microarchitecture while minimizing potentially negative effects on blood coagulation and risk of bone fracture.
  • the use of exogenous vitamin K 2 may allow for increase bone health and its associated benefits in pediatric patients.
  • pQCT and DEXA as described above, it is possible to accurately measure bone density and bone microarchitecture to demonstrate the effects of the presently claimed nutritional compositions.
  • the present disclosure provides a nutritional composition including exogenous vitamin K 2 .
  • the nutritional composition may further include a component selected from the group consisting of phosphorus, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, osteopontin and combinations thereof.
  • the term “nutritional composition” includes, but is not limited to, complete nutritional compositions, partial or incomplete nutritional compositions, and disease or condition specific nutritional compositions.
  • a complete nutritional composition i.e., those which contain all the essential macro and micro nutrients
  • Patients can receive 100% of their nutritional requirements from such complete nutritional composition.
  • a partial or incomplete nutritional composition does not contain all the essential macro and micro nutrients and cannot be used as a sole source of nutrition for the patient.
  • Partial or incomplete nutritional compositions can be used as a nutritional supplement.
  • a disease or condition specific nutritional composition is a composition that delivers nutrients or pharmaceuticals and can be a complete or partial nutritional composition.
  • exogenous vitamin K 2 can be combined with other ingredients for promotion of bone growth and bone quality.
  • exogenous vitamin K 2 could work more effectively to support bone health in pediatric patients when used in combination with a component selected from the group consisting of phosphorus, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, osteopontin and combinations thereof.
  • Exogenous vitamin K 2 may also work more effectively to support bone health when used in combination with amino acids (e.g., leucine), protein with low sulfur-containing amino acid content, lipids (n3:n6), bioactive peptides, protease inhibitors, creatine, etc.
  • amino acids e.g., leucine
  • protein with low sulfur-containing amino acid content lipids (n3:n6)
  • bioactive peptides e.g., protease inhibitors, creatine, etc.
  • the nutritional composition further includes one or more prebiotics.
  • a prebiotic is a selectively fermented ingredient that allows specific changes, both in the composition and/or activity in the gastrointestinal microflora, that confers benefits upon host well-being and health.
  • Non-limiting examples of prebiotics include fructooligosaccharides, inulin, lactulose, galactooligosaccharides, acacia gum, soyoligosaccharides, xylooligosaccharides, isomaltooligosaccharides, gentiooligosaccharides, lactosucrose, glucooligosaccharides, pecticoligosaccharides, guar gum, partially hydrolyzed guar gum, sugar alcohols, alpha glucan, beta glucan, or a combination thereof.
  • the nutritional composition further includes one or more probiotics.
  • probiotic micro-organisms are preferably microorganisms (alive, including semi-viable or weakened, and/or non-replicating), metabolites, microbial cell preparations or components of microbial cells that could confer health benefits on the host when administered in adequate amounts, more specifically that beneficially affect a host by improving its intestinal microbial balance, leading to effects on the health or well-being of the host.
  • probiotics are preferably microorganisms (alive, including semi-viable or weakened, and/or non-replicating), metabolites, microbial cell preparations or components of microbial cells that could confer health benefits on the host when administered in adequate amounts, more specifically that beneficially affect a host by improving its intestinal microbial balance, leading to effects on the health or well-being of the host.
  • the probiotics may also activate the immune function of the host.
  • probiotics include Saccharomyces, Debaromyces, Candida, Pichia, Torulopsis, Aspergillus, Rhizopus, Mucor, Penicillium, Bifidobacterium, Bacteroides, Clostridium, Fusobacterium, Melissococcus, Propionibacterium, Streptococcus, Enterococcus, Lactococcus, Staphylococcus, Peptostrepococcus, Bacillus, Pediococcus, Micrococcus, Leuconostoc, Weissella, Aerococcus, Oenococcus, Lactobacillus or a combination thereof.
  • the nutritional composition further includes one or more amino acids.
  • amino acids include Alanine, Arginine, Asparagine, Aspartate, Citrulline, Cysteine, Glutamate, Glutamine, Glycine, Histidine, Hydroxyproline, Hydroxyserine, Hydroxytyrosine, Hydroxylysine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Proline, Serine, Taurine, Threonine, Tryptophan, Tyrosine, Valine, HICA (Alpha-Hydroxyisocaproic Acid), HIVA (Alpha-Hydroxyisovaleric Acid), HIMVA (alpha-hydroxymethylvaleric acid) or a combination thereof.
  • non-limiting examples of amino acids include proline, hydroxyproline, hydroxytyrosine, hydroxylysine and hydroxyserine and combinations thereof.
  • the nutritional composition further includes one or more proteins.
  • the nutritional composition further includes one or more nucleotides.
  • the nutritional composition further includes one or more synbiotics, fish oils, nonmarine omega-3 fatty acid containing dietary fat sources, Bowman Birk Inhibitor, phytonutrients and/or antioxidants.
  • a synbiotic is a supplement that contains both a prebiotic and a probiotic that work together to improve the microflora of the intestine.
  • fish oils include docosahexaenoic acid (“DHA”) and eicosapentaenoic acid (“EPA”).
  • DHA docosahexaenoic acid
  • EPA eicosapentaenoic acid
  • phytonutrients include quercetin, curcumin and limonin.
  • Antioxidants are molecules capable of slowing or preventing the oxidation of other molecules.
  • Non-limiting examples of antioxidants include vitamin A, carotenoids, vitamin C, vitamin E, selenium, flavonoids, Lactowolfberry, Goji (wolfberry), polyphenols, lycopene, lutein, lignan, coenzyme Q10 (“CoQ10”), hesperidine and glutathione.
  • the present disclosure provides a method of making a nutritional composition.
  • the method comprises adding an effective amount of exogenous K 2 and a component selected from the group consisting of phosphorus, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, osteopontin or combinations thereof to a nutritional composition, for example, to improve bone health of pediatric patients.
  • the nutritional composition can be in an administerable form such as pharmaceutical formulations, nutritional formulations, tube-feed formulations, dietary supplements, functional foods, beverage products or a combination thereof
  • the present disclosure provides a method of tailoring a treatment or dosage to a patient based on a genetic predisposition as a parameter to assess when determining the potential for Vitamin K2 to impact bone health. Supplementation with Vitamin K2 may be more effective in individuals carrying unique genotypes.
  • a “tube feed” formulation is preferably a complete or incomplete nutritional product that is administered to an animal's gastrointestinal system, other than through oral administration, including but not limited to a nasogastric tube, orogastric tube, gastric tube, jejunostomy tube (J-tube), percutaneous endoscopic gastrostomy (PEG), port, such as a chest wall port that provides access to the stomach, jejunum and other suitable access ports.
  • a nasogastric tube orogastric tube
  • gastric tube jejunostomy tube
  • PEG percutaneous endoscopic gastrostomy
  • port such as a chest wall port that provides access to the stomach, jejunum and other suitable access ports.
  • “effective amount” is preferably an amount that prevents a deficiency, treats a disease or medical condition in an individual or, more generally, reduces symptoms, manages progression of the diseases or provides a nutritional, physiological, or medical benefit to the individual.
  • a treatment can be patient- or doctor-related.
  • the terms “individual” and “patient” are often used herein to refer to a human, the invention is not so limited. Accordingly, the terms “individual” and “patient” refer to any animal, mammal or human having or at risk for a medical condition that can benefit from the treatment.
  • animals include, but is not limited to mammals, which include, but is not limited to rodents, aquatic mammals, domestic animals such as dogs and cats, farm animals such as sheep, pigs, cows and horses, and humans. Wherein the terms animal or mammal or their plurals are used, it is contemplated that it also applies to any animals that are capable of the effect exhibited or intended to be exhibited by the context of the passage.
  • complete nutrition are preferably nutritional products that contain sufficient types and levels of macronutrients (protein, fats and carbohydrates) and micronutrients to be sufficient to be a sole source of nutrition for the animal to which it is being administered to.
  • macronutrients protein, fats and carbohydrates
  • infant nutrition are preferably nutritional products that do not contain sufficient levels of macronutrients (protein, fats and carbohydrates) or micronutrients to be sufficient to be a sole source of nutrition for the animal to which it is being administered to.
  • macronutrients protein, fats and carbohydrates
  • micronutrients to be sufficient to be a sole source of nutrition for the animal to which it is being administered to.
  • Long term administrations are preferably continuous administrations for more than 6 weeks.
  • mammal preferably includes but is not limited to rodents, aquatic mammals, domestic animals such as dogs and cats, farm animals such as sheep, pigs, cows and horses, and humans. Wherein the term mammal is used, it is contemplated that it also applies to other animals that are capable of the effect exhibited or intended to be exhibited by the mammal.
  • microorganism is meant to include the bacterium, yeast and/or fungi, a cell growth medium with the microorganism or a cell growth medium in which microorganism was cultivated.
  • a “Prebiotic” is preferably a food substances that selectively promote the growth of beneficial bacteria or inhibit the growth of pathogenic bacteria in the intestines. They are not inactivated in the stomach and/or upper intestine or absorbed in the GI tract of the person ingesting them, but they are fermented by the gastrointestinal microflora and/or by probiotics. Prebiotics are for example defined by Glenn R. Gibson and Marcel B. Roberfroid, Dietary Modulation of the Human Colonic Microbiota: Introducing the Concept of Prebiotics, J. Nutr. 1995 125: 1401-1412.
  • Short term administrations are preferably continuous administrations for less than 6 weeks.
  • treatment is preferably to both prophylactic or preventive treatment (that prevent and/or slow the development of a targeted pathologic condition or disorder) and curative, therapeutic or disease-modifying treatment, including therapeutic measures that cure, slow down, lessen symptoms of, and/or halt progression of a diagnosed pathologic condition or disorder; and treatment of patients at risk of contracting a disease or suspected to have contracted a disease, as well as patients who are ill or have been diagnosed as suffering from a disease or medical condition.
  • treatment and “treat” also refer to the maintenance and/or promotion of health in an individual not suffering from a disease but who may be susceptible to the development of an unhealthy condition, such as nitrogen imbalance or muscle loss.
  • treatment”, “treat” and “to alleviate” are also intended to include the potentiation or otherwise enhancement of one or more primary prophylactic or therapeutic measure.
  • a synbiotic is a supplement that contains both a prebiotic and a probiotic that work together to improve the microflora of the intestine.
  • normal bone growth preferably includes: during childhood and adolescence bones are sculpted by modeling, which allows for the formation of new bone at one site and the removal of old bone from another site within the same bone. This process allows individual bones to grow in size (linear growth and circumferential growth) and to shift in space. During childhood bones grow because resorption (the process of breaking down bone) occurs inside the bone while formation of new bone occurs on its outer (periosteal) surface. At puberty the bones get thicker because formation can occur on both the outer and inner (endosteal) surfaces. The remodeling process occurs throughout life and becomes the dominant process by the time that bone reaches its peak mass (typically by the early 20s).
  • remodeling In remodeling, a small amount of bone on the surface of trabeculae or in the interior of the cortex is removed and then replaced at the same site. The remodeling process does not change the shape of the bone, but it is nevertheless vital for bone health. Modeling and remodeling continue throughout life so that most of the adult skeleton is replaced about every 10 years. While remodeling predominates by early adulthood, modeling can still occur particularly in response to weakening of the bone.
  • nucleotide is preferably understood to be a subunit of deoxyribonucleic acid (“DNA”) or ribonucleic acid (“RNA”). It is an organic compound made up of a nitrogenous base, a phosphate molecule, and a sugar molecule (deoxyribose in DNA and ribose in RNA). Individual nucleotide monomers (single units) are linked together to form polymers, or long chains. Exogenous nucleotides are specifically provided by dietary supplementation.
  • the exogenous nucleotide can be in a monomeric form such as, for example, 5′ Adenosine Monophosphate (“5′-AMP”), 5′-Guanosine Monophosphate (“5′-GMP”), 5′-Cytosine Monophosphate (“5′-CMP”), 5′-Uracil Monophosphate (“5′-UMP”), 5′-Inosine Monophosphate (“5′-IMP”), 5′-Thymine Monophosphate (“5′-TMP”) or a combination thereof.
  • the exogenous nucleotide can also be in a polymeric form such as, for example, an intact RNA. There can be multiple sources of the polymeric form such as, for example, yeast RNA.
  • Nutritional products are preferably understood to further include any number of additional ingredients, including, for example one or more, vitamin, mineral, sugar, a pharmaceutically acceptable carrier, excipient, flavor agent, or colorants.
  • protein protein, “peptide”, “oligopeptides” or “polypeptide” as used herein is preferably understood to refer to any composition that includes, a single amino acids (monomers), two or more amino acids joined together by a peptide bond (dipeptide, tripeptide, or polypeptide), collagen, precursor, homolog, analog, mimetic, salt, prodrug, metabolite, or fragment thereof or combination.
  • a single amino acids monomers
  • two or more amino acids joined together by a peptide bond dipeptide, tripeptide, or polypeptide
  • collagen precursor, homolog, analog, mimetic, salt, prodrug, metabolite, or fragment thereof or combination.
  • polypeptides or peptides or proteins or oligopeptides
  • polypeptides often contain amino acids other than the 20 amino acids commonly referred to as the 20 naturally occurring amino acids, and that many amino acids, including the terminal amino acids, may be modified in a given polypeptide, either by natural processes such as glycosylation and other post-translational modifications, or by chemical modification techniques which are well known in the art.
  • polypeptides of the present invention include, but are not limited to, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of a flavanoid or a heme moiety, covalent attachment of a polynucleotide or polynucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycation, glycosylation, glycosylphosphatidyl inositol (GPI) membrane anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selen
  • phytochemicals or “phytonutrients” are non-nutritive compounds that are found in many foods. Phytochemicals are functional foods that have health benefits beyond basic nutrition, and are health promoting compounds that come from plant sources. As used herein, “Phytochemicals” and “Phytonutrients” refers to any chemical produced by a plant that imparts one or more health benefit on the user. Phytochemicals can be administered by any means, including topically, enterally, and/or parenterally. As used herein, non-limiting examples of phytochemicals and phytonutrients include those that are:
  • Phenolic compounds which include Monophenols (such as: Apiolc, Carnosol, Carvacrol, Dillapiole, Rosemarinol); Flavonoids (polyphenols) including Flavonols (such as: Quercetin, (such as: Catechins, (+)-Catechin, (+)-Gallocatechin, ( ⁇ )-Epicatechin, ( ⁇ )-Epigallocatechin, ( ⁇ )-Epigallocatechin gallate (EGCG), ( ⁇ )-Epicatechin 3-gallate, Theaflavin, Theaflavin-3-gallate, Theaflavin-3′-gallate, Theaflavin-3,3′-digallate, Thearubigins), Anthocyanins (flavonals) and Anthocyanidins (such as: Pelargonidin, Peonidin, Cyanidin, Delphinidin, Malvidin, Petunidin), Isoflavones (phytoestrogens) (such as
  • Terpenes which include Carotenoids (tetraterpenoids) including Carotenes (such as: a-Carotene, ⁇ -Carotene, ⁇ -Carotene, ⁇ -Carotene, Lycopene, Neurosporene, Phytofluene, Phytoene), and Xanthophylls (such as: Canthaxanthin, Cryptoxanthin, Zeaxanthin, Astaxanthin, Lutein, Rubixanthin); Monoterpenes (such as: Limonene, Perillyl alcohol); Saponins; Lipids including: Phytosterols (such as: Campesterol, beta Sitosterol, gamma sitosterol, Stigmasterol), Tocopherols (vitamin E), and omega-3, 6, and 9 fatty acids (such as: gamma-linolenic acid); Triterpenoid (such as: Oleanolic acid, Ursolic acid,
  • Carotenoids
  • Betalains which include Betacyanins (such as: betanin, isobetanin, probetanin, neobetanin); and Betaxanthins (non glycosidic versions) (such as: Indicaxanthin, and Vulgaxanthin);
  • Organosulfides which include Dithiolthiones (isothiocyanates) (such as: Sulphoraphane); and Thiosulphonates (allium compounds) (such as: Allyl methyl trisulfide, and Diallyl sulfide), Indoles, glucosinolates which include Indole-3-carbinol; sulforaphane; 3,3′-Diindolylmethane; Sinigrin; Allicin; Alliin; Allyl isothiocyanate; Piperine; Syn-propanethial-S-oxide;
  • Protein inhibitors which include protease inhibitors
  • antioxidant is preferably understood to include any one or more of various substances (as beta-carotene (a vitamin A precursor), vitamin C, vitamin E, and selenium) that inhibit oxidation or reactions promoted by Reactive Oxygen Species (ROS) and other radical and non-radical species.
  • beta-carotene a vitamin A precursor
  • vitamin C a vitamin C
  • vitamin E a vitamin E
  • selenium oxidation or reactions promoted by Reactive Oxygen Species (ROS) and other radical and non-radical species.
  • ROS Reactive Oxygen Species
  • vitamin is preferably understood to include any of various fat-soluble or water-soluble organic substances (non-limiting examples include vitamin A, vitamin B 1 , vitamin B 6 , vitamin B 12 , vitamin C, vitamin D, vitamin E) essential in minute amounts for normal growth and activity of the body and obtained naturally from plant and animal foods or synthetically made, and include their pro-vitamins, derivatives, and analogs.
  • the present disclosure provides a method of making a nutritional composition.
  • the method comprises adding exogenous vitamin K 2 and a component selected from the group consisting of phosphorous, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, vitamin analogs, osteopontin or combinations thereof to a nutritional composition.
  • the present disclosure provides a method of improving bone health (i.e. growth, mineralization, microarchitecture, bone organic matrix constituents, density, elasticity and strength) in pediatric patients.
  • the method comprises administering to a child in need of same a nutritional composition including an effective amount of exogenous vitamin K 2 .
  • the nutritional composition may further include a component selected from the group consisting of phosphorous, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, osteopontin or combinations thereof.
  • the present disclosure provides a method of promoting bone growth and bone quality in a pediatric patient having an underlying medical condition. The method comprises administering to a pediatric patient having an underlying medical condition a nutritional composition including an effective amount of exogenous vitamin K 2 .
  • the present disclosure provides a method of reducing the risk of bone fracture in a pediatric patient. The method comprises administering to a pediatric patient at risk of bone fracture a nutritional composition including an effective amount of exogenous vitamin K 2 .
  • the nutritional composition can include the exogenous vitamin K 2 in an amount to be administered ranging from about 1 ⁇ g/day to about 100 ⁇ g/day.
  • the exogenous vitamin K 2 can also be administered in an amount ranging from about 10 ⁇ g/day to about 95 ⁇ g/day, or from about 20 ⁇ g/day to about 90 ⁇ g/day, or from about 30 ⁇ g/day to about 85 ⁇ g/day, or from about 50 ⁇ g/day to about 80 ⁇ g/day, or 1 ⁇ g/day, 5 ⁇ g/day, or 10 ⁇ g/day, or 15 ⁇ g/day, or 20 ⁇ g/day, or 25 ⁇ g/day, or 30 ⁇ g/day, or 35 ⁇ g/day, or 40 ⁇ g/day, or 45 ⁇ g/day, or 50 ⁇ g/day, or 55 ⁇ g/day, or 60 ⁇ g/day, or 65 ⁇ g/day, or 70 ⁇ g/day, or 75 ⁇ g/day, or
  • improved osteocalcin carboxylation and improved indicies of bone health during normal growth and development in children will aid in reducing the risk of bone fracture.
  • administration of the present nutritional compositions may also result in increased bioavailability of vitamin K, which can result in increased osteocalcin carboxylation, bone strength, bone mineralization and bone microarchitecture.
  • this invention provides for a method for improving skeletal muscle health (i.e. metabolic function, lean body mass and mobility).
  • Skeletal muscle isoenzymes of creatine kinase are sensitive to Vitamin K deficiency.
  • Creatine kinase is a reaction essential to anaerobic energy production.
  • An improvement in Vitamin K status may minimize muscular fatigue and optimize energy production to support anabolic processes such as protein synthesis for muscle mass accretion.
  • Preservation of lean body mass can facilitate the maintenance of functional mobility.
  • the method comprises administering to a patient who can benefit from improved skeletal muscle health a nutritional composition including an effective amount of exogenous vitamin K 2 .
  • this invention provides for a method for reducing inflammation by administering Vitamin K2.
  • the acute control of global rates of protein synthesis is predominantly executed at the level of translational initiation with the modulation of various eukaryotic initiation factors (eIFs).
  • eIFs eukaryotic initiation factors
  • the protein kinase referred to as the mammalian target of rapamycin (mTOR), which serves as a convergence point for signaling by growth factors and amino acids to the mRNA binding step of translation initiation is involved in modulation of the phosphorylation of the binding protein for the eukaryotic initiation factor 4E, i.e. 4E-BP1. It also acts to control the phosphorylation status of the 70-kDa ribosomal protein S6 kinase (S6K1). Modulation of these translation initiation events allows for more immediate control of protein synthesis and is responsive to changes associated with acute metabolic or nutritional alterations.
  • mTOR mammalian target of rapamycin
  • S6K1 70-kDa ribosomal protein S6 kinase
  • the canonical NF- ⁇ B pathway involves nuclear transport of a p65-p50 heterodimer. Activation of NF- ⁇ B occurs when I ⁇ Bs are phosphorylated by the I ⁇ B kinase complex, leading to ubiquitination and degradation of I ⁇ B and nuclear translocation of the NF- ⁇ B dimer. Cytokines such as TNF- ⁇ are potent activators of the canonical NF- ⁇ B heterodimer, and this activation is associated with muscle protein loss.
  • vitamin K2 is administered to the rats in 0.5 mL samples, with either 25 or 50 microgram oral doses.
  • the fractional rate of synthesis is estimated from the rate of incorporation of radioactive phenylalanine into total mixed muscle protein using the specific radioactivity of serum phenylalanine as representative of the precursor pool.
  • the actual time for incorporation of the radiolabeled phenylalanine into protein is taken as the time elapsed from injection until freezing of muscle in liquid nitrogen.
  • the resulting supernatant is combined with an equal volume of SDS sample buffer and then subjected to protein immunoblot analysis.
  • Samples are analyzed for the phosphorylation status of 4E-BP1 (Thr37) and ribosomal protein S6 (Ser 235/236), the anti-phosphospecific antibodies were obtained from Cell Signaling Technology, Beverly, Mass. Additionally, samples are analyzed for phosphorylated IKK ⁇ / ⁇ (Ser176/180; Cell Signaling Technology) and phosphorylated p65 (Ser536; Cell Signaling Technology).
  • K2 Treatment of rodents with K2 results in a significant decrease in the rise of plasma TNF-a compared to LPS treated animals. Additionally, vitamin K2 results in a significant blunting of the drop in phosphorylation for IKK ⁇ / ⁇ and NF ⁇ B p65 induction compared to LPS treatment. Finally, K2 abrogates the decrease in 4E-BP1(Thr-37) and ribosomal protein S6 phosphorylation compared to LPS treatment along with a greater preservation of the fractional rate of mixed muscle protein synthesis under conditions of inflammatory sepsis.
  • this invention provides for a method for reducing inflammation, the method comprising: administering to a patient in need of same a nutritional composition comprising exogenous vitamin K2.
  • this nutritional composition further comprises a component selected from the group consisting of phosphorus, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, osteopontin and combinations thereof
  • this nutritional composition further comprises at least one antioxidant.
  • this nutritional composition further comprises at least one phytonutrient.
  • the patient is a child.
  • this invention provides for a method for reducing the effects of inflammation, the method comprising: administering to a patient in need of same a nutritional composition comprising exogenous vitamin K2.
  • this nutritional composition further comprises a component selected from the group consisting of phosphorus, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, osteopontin and combinations thereof.
  • this nutritional composition further comprises at least one antioxidant.
  • this nutritional composition further comprises at least one phytonutrient.
  • the patient is a child.
  • this invention provides for a method for preventing the effects of inflammation, the method comprising: administering to a patient in need of same a nutritional composition comprising exogenous vitamin K2.
  • this nutritional composition further comprises a component selected from the group consisting of phosphorus, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, osteopontin and combinations thereof.
  • this nutritional composition further comprises at least one antioxidant.
  • this nutritional composition further comprises at least one phytonutrient.
  • the patient is a child.
  • this invention provides for a method for decreasing the rise of plasma TNF- ⁇ under conditions of inflammation, the method comprising: administering to a patient in need of same a nutritional composition comprising exogenous vitamin K2.
  • this nutritional composition further comprises a component selected from the group consisting of phosphorus, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, osteopontin and combinations thereof.
  • this nutritional composition further comprises at least one antioxidant.
  • this nutritional composition further comprises at least one phytonutrient.
  • the patient is a child.
  • this invention provides for a method for blunting the drop in phosphorylation for IKK ⁇ / ⁇ and NF ⁇ B p65 induction under conditions of inflammation, the method comprising: administering to a patient in need of same a nutritional composition comprising exogenous vitamin K2.
  • this nutritional composition further comprises a component selected from the group consisting of phosphorus, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, osteopontin and combinations thereof.
  • this nutritional composition further comprises at least one antioxidant.
  • this nutritional composition further comprises at least one phytonutrient.
  • the patient is a child.
  • this invention provides for a method for abrogating the decrease in 4E-BP1(Thr-37) and ribosomal protein S6 phosphorylation under conditions of inflammation, the method comprising: administering to a patient in need of same a nutritional composition comprising exogenous vitamin K2.
  • this nutritional composition further comprises a component selected from the group consisting of phosphorus, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, osteopontin and combinations thereof
  • this nutritional composition further comprises at least one antioxidant.
  • this nutritional composition further comprises at least one phytonutrient.
  • the patient is a child.
  • this invention provides for a method for preserving the fractional rate of mixed muscle protein synthesis under conditions of inflammation, the method comprising: administering to a patient in need of same a nutritional composition comprising exogenous vitamin K2.
  • this nutritional composition further comprises a component selected from the group consisting of phosphorus, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, osteopontin and combinations thereof
  • this nutritional composition further comprises at least one antioxidant.
  • this nutritional composition further comprises at least one phytonutrient.
  • the patient is a child.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pediatric Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)

Abstract

Nutritional compositions and methods of making and using the nutritional compositions are provided. In a general embodiment, a nutritional composition includes exogenous vitamin K2. The nutritional compositions may further include an additional component selected from the group consisting of phosphorus, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, osteopontin and combinations thereof.

Description

PRIORITY CLAIM
This application is a divisional of U.S. patent application Ser. No. 13/395,060 filed Apr. 24, 2012, which is a National Stage of International Application No. PCT/US10/047468 filed Sep. 1, 2010, which claims benefit to Provisional Application Ser. No. 61/371,846 filed Aug. 9, 2010, U.S. Provisional Ser. No. 61/347,945 filed May 25, 2010, U.S. Provisional Application Ser. No. 61/250,847 filed Oct. 12, 2009, and U.S. Provisional Application Ser. No. 61/242,087 filed Sep. 14, 2009, the entire contents of which are incorporated herein by reference.
BACKGROUND
The present disclosure generally relates to health and nutrition. More specifically, the present disclosure relates to nutritional compositions including exogenous vitamin K2 and methods of making and using the nutritional compositions.
There are many types of nutritional compositions currently on the market. Nutritional compositions can be targeted toward certain consumer types, for example, young, elderly, athletic, etc., based on the specific ingredients of the nutritional composition. Nutritional compositions can also be formulated based on the certain physiological conditions that the nutritional compositions are intended to treat or improve.
One goal of nutritional support is to improve bone health by increasing bone density and strength and reducing the incidence of fracture risk. Due to rapidly changing bone densities in children during normal growth and development, or due to underlying medical conditions, children may require nutritional compositions to improve indices of bone health and promote bone growth and bone quality.
SUMMARY
Nutritional compositions having exogenous vitamin K2 and methods of making and using the nutritional compositions are provided. In a general embodiment, the present disclosure provides a nutritional composition including exogenous K2. The nutritional composition can be a complete nutritional or as an oral nutritional supplement (incomplete nutritional). The nutritional composition can be in a formulation designed for any mammal such as a human or an animal. The active ingredients in the nutritional composition can also be provided as a modular product. A modular product can be defined as a method of delivering one or more specific nutrients as a supplement and not intended to be used for sole source nutrition.
In an embodiment, the nutritional composition further includes one or more prebiotics. The prebiotic can be fructooligosaccharides, inulin, lactulose, galactooligosaccharides, acacia gum, soyoligosaccharides, xylooligosaccharides, isomaltooligosaccharides, gentiooligosaccharides, lactosucrose, glucooligosaccharides, pecticoligosaccharides, guar gum, partially hydrolyzed guar gum, sugar alcohols, alpha glucan, beta glucan, or a combination thereof.
In an embodiment, the nutritional composition further includes one or more probiotics. The probiotic can be Saccharomyces, Debaromyces, Candida, Pichia, Torulopsis, Aspergillus, Rhizopus, Mucor, Penicillium, Bifidobacterium, Bacteroides, Clostridium, Fusobacterium, Melissococcus, Propionibacterium, Streptococcus, Enterococcus, Lactococcus, Staphylococcus, Peptostrepococcus, Bacillus, Pediococcus, Micrococcus, Leuconostoc, Weissella, Aerococcus, Oenococcus, Lactobacillus or a combination thereof.
In another embodiment, the nutritional composition further includes one or more amino acids. The amino acid can be Alanine, Arginine, Asparagine, Aspartate, Citrulline, Cysteine, Glutamate, Glutamine, Glycine, Histidine, Hydroxyproline, Hydroxyserine, Hydroxytyrosine, Hydroxylysine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Proline, Serine, Taurine, Threonine, Tryptophan, Tyrosine, Valine, HICA (Alpha-Hydroxyisocaproic Acid), HIVA (Alpha-Hydroxyisovaleric Acid), HIMVA (alpha-hydroxymethylvaleric acid) or a combination thereof.
In an embodiment, the nutritional composition further includes one or more proteins.
In an embodiment, the nutritional composition further includes one or more nucleotides.
In an embodiment, the nutritional composition further includes one or more synbiotics, fish oils, nonmarine omega-3 fatty acid containing dietary fat sources, phytonutrients and/or antioxidants. The antioxidants can be, for example, vitamin A, vitamin B1, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, carotenoids, selenium, flavonoids, Lactowolfberry, Goji (wolfberry), polyphenols, lycopene, lutein, lignan, coenzyme Q10 (“CoQ10”), hesperidine and glutathione.
In an embodiment, the nutritional composition is in an administerable form such as pharmaceutical formulations, nutritional formulations, tube-feed formulations, dietary supplements, functional foods, beverage products or a combination thereof.
In another embodiment, the present disclosure provides a method of making a nutritional composition. The method comprises adding exogenous vitamin K2 and a component selected from the group consisting of phosphorus, magnesium, calcium, vitamin D, osteopontin, or combinations thereof to a nutritional composition.
In an alternative embodiment, the present disclosure provides a method of making a nutritional composition. The method comprises adding exogenous vitamin K2 and a component selected from the group consisting of phosphorous, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, osteopontin or combinations thereof to a nutritional composition.
In yet another embodiment, the present disclosure provides a method of improving bone health (i.e. growth, mineralization, microarchitecture, bone organic matrix constituents, density, elasticity and strength) in pediatric patients. The method comprises administering to a child in need of same a nutritional composition including an effective amount of exogenous vitamin K2. The nutritional composition may further include a component selected from the group consisting of phosphorous, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, osteopontin or combinations thereof.
In still another embodiment, the present disclosure provides a method of promoting bone growth and bone quality in a pediatric patient having an underlying medical condition. The method comprises administering to a pediatric patient having an underlying medical condition a nutritional composition including an effective amount of exogenous vitamin K2.
In another embodiment, the present disclosure provides a method of reducing the risk of bone fracture in a pediatric patient. The method comprises administering to a pediatric patient at risk of bone fracture a nutritional composition including an effective amount of exogenous vitamin K2.
In another embodiment, the present disclosure provides a method for improving skeletal muscle health (i.e. metabolic function, lean body mass and mobility). The method comprises administering to a patient who can benefit from improved skeletal muscle health a nutritional composition including an effective amount of exogenous vitamin K2.
An advantage of the present disclosure is to provide an improved nutritional composition having exogenous vitamin K2.
Another advantage of the present disclosure is to provide a method of making an improved nutritional composition.
Yet another advantage of the present disclosure is to provide a nutritional composition that promotes bone health.
Another advantage of the present disclosure is to provide a nutritional composition that promote bone growth and bone quality in patients having underlying medical conditions.
Still another advantage of the present disclosure is to provide a nutritional composition that minimizes bone fracture risk.
Additional features and advantages are described herein, and will be apparent from the following Detailed Description.
DETAILED DESCRIPTION
Maintenance of bone health is essential for mobility and the bone matrix is an important reservoir for critical minerals. On average, 90 percent of peak bone mass is acquired by the age of 18 for women and 20 for men. As such, it is important to promote proper bone health and bone growth and bone quality during the period of normal growth and development in children prior to these ages. Given the accelerated rate of bone accretion during the adolescent period, providing essential nutrients ensures the optimal functioning of the bone formation process. Further, failure to promote bone mineral density during this critical period can lead to decreased bone strength and bone tissue microarchitecture, which can elicit the onset of fragility fractures in the pediatric population.
During childhood bones grow because resorption (the process of breaking down bone) occurs inside the bone while formation of new bone occurs on its outer (periosteal) surface. At puberty the bones get thicker because formation can occur on both the outer and inner (endosteal) surfaces. The remodeling process occurs throughout life and becomes the dominant process by the time that bone reaches its peak mass (typically by the early 20s). In remodeling, a small amount of bone on the surface of trabeculae or in the interior of the cortex is removed and then replaced at the same site. The remodeling process does not change the shape of the bone, but it is nevertheless vital for bone health. Modeling and remodeling continue throughout life so that most of the adult skeleton is replaced about every 10 years. While remodeling predominates by early adulthood, modeling can still occur particularly in response to weakening of the bone.
While Calcium and vitamin D are important nutrients for the development of the inorganic matrix of the bone, several nutrients are needed for normal development of the organic matrix of bone. Specifically, adequate vitamin K, and trace minerals such as zinc, copper, iron nutriture are required for the normal metabolism of noncollagenous proteins such as osteocalcin, osteopontin. Provision of these nutrients during rapid growth, can lead to prevention of osteomalacia and osteoporosis later in life. This improves quality of life and also will save healthcare costs related to hip fractures.
Vitamin K denotes a group of lipophilic, hydrophobic and essential vitamins having a common chemical ring structure (napthoquinone). The two most important forms of vitamin K are vitamin K1, a single compound known as phylloquinone or phytomenadione, and vitamin K2, a series of vitamers known as menaquinones or menatetrenones. There are also several synthetic forms of vitamin K including, for example, vitamins K3, K4 and K5.
Vitamin K1 is the major form of vitamin K in a normal diet and is synthesized by plants including, for example, certain plant oils such as canola and soybean and in green leafy vegetables such as spinach, swiss chard, broccoli, cabbage, cauliflower, kale, and brussels sprouts.
Vitamin K2 is a group of compounds called menaquinones (“MK”) having side chains composed of a variable number of unsaturated isoprenoid residues generally designated as MK-n, where n specifies the number of isoprenoids. The most common MKs are MK-4 and MK-7. MK-4 is typically synthesized by animal organs and muscle, while MK-7 is typically synthesized by bacteria during fermentation. Accordingly, MK-7 is particularly abundant in fermented products including cheese, curd cheese and natto (fermented soybeans) and has a particularly long half-life when compared to vitamin K1.
The estimated average requirement for vitamin K in children ages 1 to 18 years in the United States is based upon median intakes of vitamin K for adults. These levels are designed to meet the vitamin K levels required for normal blood coagulation and not other vitamin K-dependent proteins such as osteocalcin. The ratio of undercarboxylated (i.e., inactive) to carboxylated osteocalcin can be a surrogate marker for vitamin K status. Recent evidence suggests that children between the ages of 6 and 18 years of age have elevated levels of undercarboxylated osteocalcin relative to adults. Rather than attempting to increase the intake levels via higher vitamin K1 intake, vitamin K2 allows for administration of a more potent form of vitamin K without negatively impacting parameters of anticoagulation.
As compared to vitamin K1, vitamin K2 provides better absorption and more stable serum levels through a longer half-life. The improved bioavailability of vitamin K2 to extrahepatic tissue may also allow for a greater impact on bone health (i.e. mineralization, microarchitecture and strength) during normal growth and development. Therefore, vitamin K2 provides for a more potent form of the vitamin in which its enhanced bioavailability can impact bone health during normal growth and development.
Additionally, there exists several medical conditions in which bone growth and bone quality in pediatric patients may be compromised. Such conditions may include, for example, developmental delay, failure-to-thrive, neuromuscular dysfunction, severe food allergy and inflammatory bowel disease (e.g., Crohns disease or ulcerative colitis). For example, the incidence of low bone mass in children having inflammatory bowel disease (“IBD”) ranges from about 30-50%. Vitamin K is a cited nutrition deficiency in this population and its limited bioavailability may reduce osteocalcin carboxylation as well as reduce bone strength, bone mineralization and bone microarchitecture. Accordingly, children suffering from any of the above-mentioned medical conditions may benefit from a more effective dose of vitamin K.
Rather than attempting to increase the intake levels via higher vitamin K1 intake, Vitamin K2 allows for a more potent form of vitamin K without negatively impacting parameters of anticoagulation. Specifically, vitamin K2 provides better absorption and more stable serum levels through a longer half-life when compared to phylloquinones (vitamin K1). Improved bioavailability of vitamin K2 to extraheptic tissue may allow for a greater impact for improving musculoskeletal health in patients with inflammatory bowel disease (IBD) (Crohn's Disease and Colitis), especially pediatric patients. The incidence of low bone mass ranges from 30-50% in children with IBD. Vitamin K is a cited nutrition deficiency in this population and its limited availability may reduce osteocalcin carboxylation as well as reduce bone strength, bone mineralization and bone micro-architecture. In addition, a low vitamin K status may be a causative factor in Crohn's Disease-associated osteopenia. The osteopenia and elevated rate of bone resorption noted in some Crohn's Disease patients is a multifactorial process and vitamin K deficiency is certainly only one factor in this process. Low vitamin K levels can lead to an increase in the rate of bone resorption, without a compensatory increase in the rate of bone formation. An increased rate of bone turnover is associated with an increased risk of bone loss in Crohn's Disease patients. In terms of nutrition-related etiological factors for osteopenia, there are indications that in patients with longstanding Crohn's Disease, vitamin K deficiency has a greater influence on bone turnover than serum 25(0H) vitamin D concentrations. Vitamin K2 may serve as a critical micronutrient for optimizing bone regulation in this target population.
Further, vitamin K2 may also be effective for bone health in pediatric patients undergoing concurrent drug treatments including, for example, corticosteroids, bisphosphonates or anti-coagulative drugs. Similarly, pediatric patients undergoing biologic therapies or having conditions of gastrointestinal (“GI”) impairment including, for example, short bowel syndrome, ulcerative colitis, celiac disease, cystic fibrosis, renal dysfunction and androgen deficiency, gluten intolerance, Crohns disease or severe allergy, may also benefit from administration of nutritional compositions having exogenous vitamin K2.
Applicant has surprisingly found that administering exogenous vitamin K2 as part of a nutritional formulation will improve osteocalcin carboxylation and improve indicies of bone health during normal growth and development in children. Additionally, vitamin K2 supplementation can also promote bone growth and bone quality in pediatric patients with underlying medical conditions in which bone growth and bone quality may be compromised. As a result, Applicant has found that administration of exogenous vitamin K2 increases bone density and improves bone tissue microarchitecture in pediatric patients, thereby reducing the incidence for fracture risk. The effects of vitamin K2 may be seen directly on bone quality such that this form of vitamin K modulates formation of proteins in the organic matrix of the bone involved in microarchitectural morphology, mineralization, density, elasticity and mechanical stiffness, as measured by peripheral quantitative computer tomography (“pQCT”) or Dual Energy X-ray absorptiometry (“DEXA”). Vitamin K2 may also be effective for bone health in patients undergoing concurrent drug treatment.
Generally speaking, bone density is expressed as the relationship between bone mass (expressed as the degree of photon attenuation through the bone, or bone mineral content (BMC)) and the image of the bone on a film (i.e., the area) (expressed as BMC/cm2). Additionally, pQCT is a procedure that evaluates peripheral bone in 3 dimensions (volumetric) and is commonly applied to the forearm or tibia. A radiation source (typically x-rays) and a sensor revolve around the bone under examination, which is them reconstructed on the computer screen in a three-dimensional (3-D) image. pQCT is an optimal technique for evaluating bone geometry even though sensitivity varies with the site under evaluation. Unlike most other techniques, pQCT measures true bone density (volumetric mineral bone density) because it normalizes the bone mineral content derived not from the projected area but rather from the volume of the examined bone. pQCT can also be used to calculate the SSI, an index of bone resistance to torsion. The index takes into account bone geometry and the bone's mineral characteristics. See, Geometry and bone density, Radetti, G., et al., Panminerva Med 2006; 48:181-6.
DEXA is based on x-ray spectrometry and it's fundamental principle is based on the degree of attenuation of x-rays emitted from 2 different sources of energy. DEXA is normally used to evaluate lumbar or proximal femoral bone mineralization. DEXA has an accuracy of 4-10% and a coefficient of variation of 1-1.5%. See, Id.
Accordingly, the present disclosure relates to nutritional compositions including exogenous K2 and methods of making and using the nutritional compositions. The present disclosure also relates to the use of pQCT and DEXA to measure bone density and bone tissue microarchitecture. Embodiments of the nutritional compositions of the present disclosure can promote the increase of bone density, mineralization and mechanical stiffness as well as improved bone tissue microarchitecture while minimizing potentially negative effects on blood coagulation and risk of bone fracture. Thus, the use of exogenous vitamin K2 may allow for increase bone health and its associated benefits in pediatric patients. Using pQCT and DEXA, as described above, it is possible to accurately measure bone density and bone microarchitecture to demonstrate the effects of the presently claimed nutritional compositions.
In a general embodiment, the present disclosure provides a nutritional composition including exogenous vitamin K2. The nutritional composition may further include a component selected from the group consisting of phosphorus, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, osteopontin and combinations thereof.
As used herein, the term “nutritional composition” includes, but is not limited to, complete nutritional compositions, partial or incomplete nutritional compositions, and disease or condition specific nutritional compositions. A complete nutritional composition (i.e., those which contain all the essential macro and micro nutrients) can be used as a sole source of nutrition for the patient. Patients can receive 100% of their nutritional requirements from such complete nutritional composition. A partial or incomplete nutritional composition does not contain all the essential macro and micro nutrients and cannot be used as a sole source of nutrition for the patient. Partial or incomplete nutritional compositions can be used as a nutritional supplement. A disease or condition specific nutritional composition is a composition that delivers nutrients or pharmaceuticals and can be a complete or partial nutritional composition.
The exogenous vitamin K2 can be combined with other ingredients for promotion of bone growth and bone quality. For example, exogenous vitamin K2 could work more effectively to support bone health in pediatric patients when used in combination with a component selected from the group consisting of phosphorus, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, osteopontin and combinations thereof. Exogenous vitamin K2 may also work more effectively to support bone health when used in combination with amino acids (e.g., leucine), protein with low sulfur-containing amino acid content, lipids (n3:n6), bioactive peptides, protease inhibitors, creatine, etc.
In an embodiment, the nutritional composition further includes one or more prebiotics. As used herein, a prebiotic is a selectively fermented ingredient that allows specific changes, both in the composition and/or activity in the gastrointestinal microflora, that confers benefits upon host well-being and health. Non-limiting examples of prebiotics include fructooligosaccharides, inulin, lactulose, galactooligosaccharides, acacia gum, soyoligosaccharides, xylooligosaccharides, isomaltooligosaccharides, gentiooligosaccharides, lactosucrose, glucooligosaccharides, pecticoligosaccharides, guar gum, partially hydrolyzed guar gum, sugar alcohols, alpha glucan, beta glucan, or a combination thereof.
In an embodiment, the nutritional composition further includes one or more probiotics. As used herein, probiotic micro-organisms (hereinafter “probiotics”) are preferably microorganisms (alive, including semi-viable or weakened, and/or non-replicating), metabolites, microbial cell preparations or components of microbial cells that could confer health benefits on the host when administered in adequate amounts, more specifically that beneficially affect a host by improving its intestinal microbial balance, leading to effects on the health or well-being of the host. In general, it is believed that these micro-organisms inhibit or influence the growth and/or metabolism of pathogenic bacteria in the intestinal tract. The probiotics may also activate the immune function of the host. For this reason, there have been many different approaches to include probiotics into food products. Non-limiting examples of probiotics include Saccharomyces, Debaromyces, Candida, Pichia, Torulopsis, Aspergillus, Rhizopus, Mucor, Penicillium, Bifidobacterium, Bacteroides, Clostridium, Fusobacterium, Melissococcus, Propionibacterium, Streptococcus, Enterococcus, Lactococcus, Staphylococcus, Peptostrepococcus, Bacillus, Pediococcus, Micrococcus, Leuconostoc, Weissella, Aerococcus, Oenococcus, Lactobacillus or a combination thereof.
In another embodiment, the nutritional composition further includes one or more amino acids. Non-limiting examples of amino acids include Alanine, Arginine, Asparagine, Aspartate, Citrulline, Cysteine, Glutamate, Glutamine, Glycine, Histidine, Hydroxyproline, Hydroxyserine, Hydroxytyrosine, Hydroxylysine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Proline, Serine, Taurine, Threonine, Tryptophan, Tyrosine, Valine, HICA (Alpha-Hydroxyisocaproic Acid), HIVA (Alpha-Hydroxyisovaleric Acid), HIMVA (alpha-hydroxymethylvaleric acid) or a combination thereof In a preferred embodiment, non-limiting examples of amino acids include proline, hydroxyproline, hydroxytyrosine, hydroxylysine and hydroxyserine and combinations thereof.
In an embodiment, the nutritional composition further includes one or more proteins.
In an embodiment, the nutritional composition further includes one or more nucleotides.
In an embodiment, the nutritional composition further includes one or more synbiotics, fish oils, nonmarine omega-3 fatty acid containing dietary fat sources, Bowman Birk Inhibitor, phytonutrients and/or antioxidants. As used herein, a synbiotic is a supplement that contains both a prebiotic and a probiotic that work together to improve the microflora of the intestine. Non-limiting examples of fish oils include docosahexaenoic acid (“DHA”) and eicosapentaenoic acid (“EPA”). Non-limiting examples of phytonutrients include quercetin, curcumin and limonin. Antioxidants are molecules capable of slowing or preventing the oxidation of other molecules. Non-limiting examples of antioxidants include vitamin A, carotenoids, vitamin C, vitamin E, selenium, flavonoids, Lactowolfberry, Goji (wolfberry), polyphenols, lycopene, lutein, lignan, coenzyme Q10 (“CoQ10”), hesperidine and glutathione.
In another embodiment, the present disclosure provides a method of making a nutritional composition. The method comprises adding an effective amount of exogenous K2 and a component selected from the group consisting of phosphorus, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, osteopontin or combinations thereof to a nutritional composition, for example, to improve bone health of pediatric patients. The nutritional composition can be in an administerable form such as pharmaceutical formulations, nutritional formulations, tube-feed formulations, dietary supplements, functional foods, beverage products or a combination thereof
In another embodiment, the present disclosure provides a method of tailoring a treatment or dosage to a patient based on a genetic predisposition as a parameter to assess when determining the potential for Vitamin K2 to impact bone health. Supplementation with Vitamin K2 may be more effective in individuals carrying unique genotypes.
As used herein, a “tube feed” formulation is preferably a complete or incomplete nutritional product that is administered to an animal's gastrointestinal system, other than through oral administration, including but not limited to a nasogastric tube, orogastric tube, gastric tube, jejunostomy tube (J-tube), percutaneous endoscopic gastrostomy (PEG), port, such as a chest wall port that provides access to the stomach, jejunum and other suitable access ports.
As used herein, “effective amount” is preferably an amount that prevents a deficiency, treats a disease or medical condition in an individual or, more generally, reduces symptoms, manages progression of the diseases or provides a nutritional, physiological, or medical benefit to the individual. A treatment can be patient- or doctor-related. In addition, while the terms “individual” and “patient” are often used herein to refer to a human, the invention is not so limited. Accordingly, the terms “individual” and “patient” refer to any animal, mammal or human having or at risk for a medical condition that can benefit from the treatment.
As used herein, animals include, but is not limited to mammals, which include, but is not limited to rodents, aquatic mammals, domestic animals such as dogs and cats, farm animals such as sheep, pigs, cows and horses, and humans. Wherein the terms animal or mammal or their plurals are used, it is contemplated that it also applies to any animals that are capable of the effect exhibited or intended to be exhibited by the context of the passage.
As used herein, “complete nutrition” are preferably nutritional products that contain sufficient types and levels of macronutrients (protein, fats and carbohydrates) and micronutrients to be sufficient to be a sole source of nutrition for the animal to which it is being administered to.
As used herein, “incomplete nutrition” are preferably nutritional products that do not contain sufficient levels of macronutrients (protein, fats and carbohydrates) or micronutrients to be sufficient to be a sole source of nutrition for the animal to which it is being administered to.
As used herein, “Long term administrations” are preferably continuous administrations for more than 6 weeks.
As used herein, mammal preferably includes but is not limited to rodents, aquatic mammals, domestic animals such as dogs and cats, farm animals such as sheep, pigs, cows and horses, and humans. Wherein the term mammal is used, it is contemplated that it also applies to other animals that are capable of the effect exhibited or intended to be exhibited by the mammal.
The term “microorganism” is meant to include the bacterium, yeast and/or fungi, a cell growth medium with the microorganism or a cell growth medium in which microorganism was cultivated.
As used herein, a “Prebiotic” is preferably a food substances that selectively promote the growth of beneficial bacteria or inhibit the growth of pathogenic bacteria in the intestines. They are not inactivated in the stomach and/or upper intestine or absorbed in the GI tract of the person ingesting them, but they are fermented by the gastrointestinal microflora and/or by probiotics. Prebiotics are for example defined by Glenn R. Gibson and Marcel B. Roberfroid, Dietary Modulation of the Human Colonic Microbiota: Introducing the Concept of Prebiotics, J. Nutr. 1995 125: 1401-1412.
As used herein, “Short term administrations” are preferably continuous administrations for less than 6 weeks.
As used herein, the terms “treatment”, “treat” and “to alleviate” is preferably to both prophylactic or preventive treatment (that prevent and/or slow the development of a targeted pathologic condition or disorder) and curative, therapeutic or disease-modifying treatment, including therapeutic measures that cure, slow down, lessen symptoms of, and/or halt progression of a diagnosed pathologic condition or disorder; and treatment of patients at risk of contracting a disease or suspected to have contracted a disease, as well as patients who are ill or have been diagnosed as suffering from a disease or medical condition. The terms “treatment” and “treat” also refer to the maintenance and/or promotion of health in an individual not suffering from a disease but who may be susceptible to the development of an unhealthy condition, such as nitrogen imbalance or muscle loss. The terms “treatment”, “treat” and “to alleviate” are also intended to include the potentiation or otherwise enhancement of one or more primary prophylactic or therapeutic measure.
As used herein, a synbiotic is a supplement that contains both a prebiotic and a probiotic that work together to improve the microflora of the intestine.
As used herein, “normal bone growth” preferably includes: during childhood and adolescence bones are sculpted by modeling, which allows for the formation of new bone at one site and the removal of old bone from another site within the same bone. This process allows individual bones to grow in size (linear growth and circumferential growth) and to shift in space. During childhood bones grow because resorption (the process of breaking down bone) occurs inside the bone while formation of new bone occurs on its outer (periosteal) surface. At puberty the bones get thicker because formation can occur on both the outer and inner (endosteal) surfaces. The remodeling process occurs throughout life and becomes the dominant process by the time that bone reaches its peak mass (typically by the early 20s). In remodeling, a small amount of bone on the surface of trabeculae or in the interior of the cortex is removed and then replaced at the same site. The remodeling process does not change the shape of the bone, but it is nevertheless vital for bone health. Modeling and remodeling continue throughout life so that most of the adult skeleton is replaced about every 10 years. While remodeling predominates by early adulthood, modeling can still occur particularly in response to weakening of the bone.
As used herein, a “nucleotide” is preferably understood to be a subunit of deoxyribonucleic acid (“DNA”) or ribonucleic acid (“RNA”). It is an organic compound made up of a nitrogenous base, a phosphate molecule, and a sugar molecule (deoxyribose in DNA and ribose in RNA). Individual nucleotide monomers (single units) are linked together to form polymers, or long chains. Exogenous nucleotides are specifically provided by dietary supplementation. The exogenous nucleotide can be in a monomeric form such as, for example, 5′ Adenosine Monophosphate (“5′-AMP”), 5′-Guanosine Monophosphate (“5′-GMP”), 5′-Cytosine Monophosphate (“5′-CMP”), 5′-Uracil Monophosphate (“5′-UMP”), 5′-Inosine Monophosphate (“5′-IMP”), 5′-Thymine Monophosphate (“5′-TMP”) or a combination thereof. The exogenous nucleotide can also be in a polymeric form such as, for example, an intact RNA. There can be multiple sources of the polymeric form such as, for example, yeast RNA.
Nutritional products are preferably understood to further include any number of additional ingredients, including, for example one or more, vitamin, mineral, sugar, a pharmaceutically acceptable carrier, excipient, flavor agent, or colorants.
The term “protein”, “peptide”, “oligopeptides” or “polypeptide” as used herein is preferably understood to refer to any composition that includes, a single amino acids (monomers), two or more amino acids joined together by a peptide bond (dipeptide, tripeptide, or polypeptide), collagen, precursor, homolog, analog, mimetic, salt, prodrug, metabolite, or fragment thereof or combination. For the sake of clarity, the use of any of the above terms is interchangeable unless otherwise specified. It will be appreciated that polypeptides (or peptides or proteins or oligopeptides) often contain amino acids other than the 20 amino acids commonly referred to as the 20 naturally occurring amino acids, and that many amino acids, including the terminal amino acids, may be modified in a given polypeptide, either by natural processes such as glycosylation and other post-translational modifications, or by chemical modification techniques which are well known in the art. Among the known modifications which may be present in polypeptides of the present invention include, but are not limited to, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of a flavanoid or a heme moiety, covalent attachment of a polynucleotide or polynucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycation, glycosylation, glycosylphosphatidyl inositol (GPI) membrane anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to polypeptides such as arginylation, and ubiquitination. The term “protein” also includes “artificial proteins” which refers to linear or non-linear polypeptides, consisting of alternating repeats of a peptide
As used herein, “phytochemicals” or “phytonutrients” are non-nutritive compounds that are found in many foods. Phytochemicals are functional foods that have health benefits beyond basic nutrition, and are health promoting compounds that come from plant sources. As used herein, “Phytochemicals” and “Phytonutrients” refers to any chemical produced by a plant that imparts one or more health benefit on the user. Phytochemicals can be administered by any means, including topically, enterally, and/or parenterally. As used herein, non-limiting examples of phytochemicals and phytonutrients include those that are:
1. Phenolic compounds which include Monophenols (such as: Apiolc, Carnosol, Carvacrol, Dillapiole, Rosemarinol); Flavonoids (polyphenols) including Flavonols (such as: Quercetin, (such as: Catechins, (+)-Catechin, (+)-Gallocatechin, (−)-Epicatechin, (−)-Epigallocatechin, (−)-Epigallocatechin gallate (EGCG), (−)-Epicatechin 3-gallate, Theaflavin, Theaflavin-3-gallate, Theaflavin-3′-gallate, Theaflavin-3,3′-digallate, Thearubigins), Anthocyanins (flavonals) and Anthocyanidins (such as: Pelargonidin, Peonidin, Cyanidin, Delphinidin, Malvidin, Petunidin), Isoflavones (phytoestrogens) (such as: Daidzein (formononetin), Genistein (biochanin A), Glycitein), Dihydroflavonols, Chalcones, Coumestans (phytoestrogens), and Coumestrol; Phenolic acids (such as: Ellagic acid, Gallic acid, Tannic acid, Vanillin, Curcumin); Hydroxycinnamic acids (such as: Caffeic acid, Chlorogenic acid, Cinnamic acid, Ferulic acid, Coumarin); Lignans (phytoestrogens), Silymarin, Secoisolariciresinol, Pinoresinol and lariciresinol); Tyrosol esters (such as: Tyrosol, Hydroxytyrosol, Oleocanthal, Oleuropein); Stilbenoids (such as: Resveratrol, Pterostilbene, Piceatannol) and Punicalagins;
2. Terpenes (isoprenoids) which include Carotenoids (tetraterpenoids) including Carotenes (such as: a-Carotene, β-Carotene, γ-Carotene, δ-Carotene, Lycopene, Neurosporene, Phytofluene, Phytoene), and Xanthophylls (such as: Canthaxanthin, Cryptoxanthin, Zeaxanthin, Astaxanthin, Lutein, Rubixanthin); Monoterpenes (such as: Limonene, Perillyl alcohol); Saponins; Lipids including: Phytosterols (such as: Campesterol, beta Sitosterol, gamma sitosterol, Stigmasterol), Tocopherols (vitamin E), and omega-3, 6, and 9 fatty acids (such as: gamma-linolenic acid); Triterpenoid (such as: Oleanolic acid, Ursolic acid, Betulinic acid, Moronic acid);
3. Betalains which include Betacyanins (such as: betanin, isobetanin, probetanin, neobetanin); and Betaxanthins (non glycosidic versions) (such as: Indicaxanthin, and Vulgaxanthin);
4. Organosulfides which include Dithiolthiones (isothiocyanates) (such as: Sulphoraphane); and Thiosulphonates (allium compounds) (such as: Allyl methyl trisulfide, and Diallyl sulfide), Indoles, glucosinolates which include Indole-3-carbinol; sulforaphane; 3,3′-Diindolylmethane; Sinigrin; Allicin; Alliin; Allyl isothiocyanate; Piperine; Syn-propanethial-S-oxide;
5. Protein inhibitors which include protease inhibitors;
6. Other organic acids which include Oxalic acid, Phytic acid (inositol hexaphosphate); Tartaric acid; and Anacardic acid; and
7. combinations thereof.
As used herein the term “antioxidant” is preferably understood to include any one or more of various substances (as beta-carotene (a vitamin A precursor), vitamin C, vitamin E, and selenium) that inhibit oxidation or reactions promoted by Reactive Oxygen Species (ROS) and other radical and non-radical species.
As used herein the term “vitamin” is preferably understood to include any of various fat-soluble or water-soluble organic substances (non-limiting examples include vitamin A, vitamin B1, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E) essential in minute amounts for normal growth and activity of the body and obtained naturally from plant and animal foods or synthetically made, and include their pro-vitamins, derivatives, and analogs.
As used in this specification and the appended claims, the singular forms “a”, “an” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a polypeptide” includes a mixture of two or more polypeptides, and the like.
As used herein, “about,” is preferably understood to refer to numbers in a range of numerals. Moreover, all numerical ranges herein should be understood to include all integer, whole or fractions, within the range.
In an alternative embodiment, the present disclosure provides a method of making a nutritional composition. The method comprises adding exogenous vitamin K2 and a component selected from the group consisting of phosphorous, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, vitamin analogs, osteopontin or combinations thereof to a nutritional composition. In yet another embodiment, the present disclosure provides a method of improving bone health (i.e. growth, mineralization, microarchitecture, bone organic matrix constituents, density, elasticity and strength) in pediatric patients. The method comprises administering to a child in need of same a nutritional composition including an effective amount of exogenous vitamin K2. The nutritional composition may further include a component selected from the group consisting of phosphorous, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, osteopontin or combinations thereof. In still another embodiment, the present disclosure provides a method of promoting bone growth and bone quality in a pediatric patient having an underlying medical condition. The method comprises administering to a pediatric patient having an underlying medical condition a nutritional composition including an effective amount of exogenous vitamin K2. In another embodiment, the present disclosure provides a method of reducing the risk of bone fracture in a pediatric patient. The method comprises administering to a pediatric patient at risk of bone fracture a nutritional composition including an effective amount of exogenous vitamin K2.
The nutritional composition can include the exogenous vitamin K2 in an amount to be administered ranging from about 1 μg/day to about 100 μg/day. The exogenous vitamin K2 can also be administered in an amount ranging from about 10 μg/day to about 95 μg/day, or from about 20 μg/day to about 90 μg/day, or from about 30 μg/day to about 85 μg/day, or from about 50 μg/day to about 80 μg/day, or 1 μg/day, 5 μg/day, or 10 μg/day, or 15 μg/day, or 20 μg/day, or 25 μg/day, or 30 μg/day, or 35 μg/day, or 40 μg/day, or 45 μg/day, or 50 μg/day, or 55 μg/day, or 60 μg/day, or 65 μg/day, or 70 μg/day, or 75 μg/day, or 80 μg/day, or 85 μg/day, or 90 μg/day, 95 μg/day, or 100 μg/day.
By using the nutritional compositions in embodiments of the present disclosure, improved osteocalcin carboxylation and improved indicies of bone health during normal growth and development in children will aid in reducing the risk of bone fracture. Similarly, administration of the present nutritional compositions may also result in increased bioavailability of vitamin K, which can result in increased osteocalcin carboxylation, bone strength, bone mineralization and bone microarchitecture.
In another embodiment, this invention provides for a method for improving skeletal muscle health (i.e. metabolic function, lean body mass and mobility). Skeletal muscle isoenzymes of creatine kinase are sensitive to Vitamin K deficiency. Creatine kinase is a reaction essential to anaerobic energy production. An improvement in Vitamin K status may minimize muscular fatigue and optimize energy production to support anabolic processes such as protein synthesis for muscle mass accretion. Preservation of lean body mass can facilitate the maintenance of functional mobility. The method comprises administering to a patient who can benefit from improved skeletal muscle health a nutritional composition including an effective amount of exogenous vitamin K2.
In another embodiment, this invention provides for a method for reducing inflammation by administering Vitamin K2.
K2 and Inflammation
The acute control of global rates of protein synthesis is predominantly executed at the level of translational initiation with the modulation of various eukaryotic initiation factors (eIFs). The protein kinase referred to as the mammalian target of rapamycin (mTOR), which serves as a convergence point for signaling by growth factors and amino acids to the mRNA binding step of translation initiation is involved in modulation of the phosphorylation of the binding protein for the eukaryotic initiation factor 4E, i.e. 4E-BP1. It also acts to control the phosphorylation status of the 70-kDa ribosomal protein S6 kinase (S6K1). Modulation of these translation initiation events allows for more immediate control of protein synthesis and is responsive to changes associated with acute metabolic or nutritional alterations.
The canonical NF-κB pathway involves nuclear transport of a p65-p50 heterodimer. Activation of NF-κB occurs when IκBs are phosphorylated by the IκB kinase complex, leading to ubiquitination and degradation of IκB and nuclear translocation of the NF-κB dimer. Cytokines such as TNF-α are potent activators of the canonical NF-κB heterodimer, and this activation is associated with muscle protein loss.
Methods
Male Sprague-Dawley rats (175 g) are kept on a 12-h light:dark cycle with food (Harlan-Teklad Rodent Chow, Madison, Wis.) and water provided freely. Animals are administered daily doses of vitamin K2 (MK-7) or saline (control) via oral gavage over 7 days. Stock solutions of vitamin K2 are prepared containing 3.5 g/L HCO-60 and 1 g/L of M&-7 in buffer A (0.15 M NaCl, 0.05 M Tris-HCl, pH 7.5). The K2 is dissolved by sonication during five pulses of 5 set with an amplitude of 6 pm. Solutions thus obtained are clear, homogeneous, and stable. Shortly before vitamin K administration the stock solutions are diluted five times with buffer A, leading to a final HCO-60 concentration of 0.7 g/L. Further dilutions (as required) are made with 0.7 g/L HCO-60 in buffer A. Each dilution step is followed by sonication as described above. In all cases vitamin K2 is administered to the rats in 0.5 mL samples, with either 25 or 50 microgram oral doses.
On the final day (Day 7), rodents are administered vitamin K2 and 2 hours later were given an IP dose of LPS (Escherichia coli serotype O111:B4, L2630, Sigma) intraperitoneally (0.5 mg/kg of body weight). Four hours later animals are sacrificed.
Measurement of Protein Synthesis—The fractional rate of synthesis (Ks) is estimated from the rate of incorporation of radioactive phenylalanine into total mixed muscle protein using the specific radioactivity of serum phenylalanine as representative of the precursor pool. The actual time for incorporation of the radiolabeled phenylalanine into protein is taken as the time elapsed from injection until freezing of muscle in liquid nitrogen.
Analysis of mTOR Signaling to eIFs—Gastrocnemius muscles are weighed and homogenized in 7 volumes of buffer containing 20 mM HEPES (pH 7.4), 100 mM potassium chloride, 0.2 mM EDTA, 2 mM EGTA, 50 mM sodium fluoride, 50 mM glycerophosphate, 0.1 mM phenylmethylsulfonyl fluoride, 1 mM benzamidine, 1 mM dithiothreitol (DTT), and 0.5 mM sodium vanadate. The remaining homogenate is centrifuged at 10,000×g for 10 min at 4° C. The resulting supernatant is combined with an equal volume of SDS sample buffer and then subjected to protein immunoblot analysis. Samples are analyzed for the phosphorylation status of 4E-BP1 (Thr37) and ribosomal protein S6 (Ser 235/236), the anti-phosphospecific antibodies were obtained from Cell Signaling Technology, Beverly, Mass. Additionally, samples are analyzed for phosphorylated IKKα/β (Ser176/180; Cell Signaling Technology) and phosphorylated p65 (Ser536; Cell Signaling Technology).
Results
Treatment of rodents with K2 results in a significant decrease in the rise of plasma TNF-a compared to LPS treated animals. Additionally, vitamin K2 results in a significant blunting of the drop in phosphorylation for IKKα/β and NFκB p65 induction compared to LPS treatment. Finally, K2 abrogates the decrease in 4E-BP1(Thr-37) and ribosomal protein S6 phosphorylation compared to LPS treatment along with a greater preservation of the fractional rate of mixed muscle protein synthesis under conditions of inflammatory sepsis.
In another embodiment, this invention provides for a method for reducing inflammation, the method comprising: administering to a patient in need of same a nutritional composition comprising exogenous vitamin K2. In another embodiment, this nutritional composition further comprises a component selected from the group consisting of phosphorus, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, osteopontin and combinations thereof In another embodiment, this nutritional composition further comprises at least one antioxidant. In another embodiment, this nutritional composition further comprises at least one phytonutrient. In another embodiment, the patient is a child.
In another embodiment, this invention provides for a method for reducing the effects of inflammation, the method comprising: administering to a patient in need of same a nutritional composition comprising exogenous vitamin K2. In another embodiment, this nutritional composition further comprises a component selected from the group consisting of phosphorus, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, osteopontin and combinations thereof. In another embodiment, this nutritional composition further comprises at least one antioxidant. In another embodiment, this nutritional composition further comprises at least one phytonutrient. In another embodiment, the patient is a child.
In another embodiment, this invention provides for a method for preventing the effects of inflammation, the method comprising: administering to a patient in need of same a nutritional composition comprising exogenous vitamin K2. In another embodiment, this nutritional composition further comprises a component selected from the group consisting of phosphorus, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, osteopontin and combinations thereof. In another embodiment, this nutritional composition further comprises at least one antioxidant. In another embodiment, this nutritional composition further comprises at least one phytonutrient. In another embodiment, the patient is a child.
In another embodiment, this invention provides for a method for decreasing the rise of plasma TNF-α under conditions of inflammation, the method comprising: administering to a patient in need of same a nutritional composition comprising exogenous vitamin K2. In another embodiment, this nutritional composition further comprises a component selected from the group consisting of phosphorus, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, osteopontin and combinations thereof. In another embodiment, this nutritional composition further comprises at least one antioxidant. In another embodiment, this nutritional composition further comprises at least one phytonutrient. In another embodiment, the patient is a child.
In another embodiment, this invention provides for a method for blunting the drop in phosphorylation for IKKα/β and NFκB p65 induction under conditions of inflammation, the method comprising: administering to a patient in need of same a nutritional composition comprising exogenous vitamin K2. In another embodiment, this nutritional composition further comprises a component selected from the group consisting of phosphorus, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, osteopontin and combinations thereof. In another embodiment, this nutritional composition further comprises at least one antioxidant. In another embodiment, this nutritional composition further comprises at least one phytonutrient. In another embodiment, the patient is a child.
In another embodiment, this invention provides for a method for abrogating the decrease in 4E-BP1(Thr-37) and ribosomal protein S6 phosphorylation under conditions of inflammation, the method comprising: administering to a patient in need of same a nutritional composition comprising exogenous vitamin K2. In another embodiment, this nutritional composition further comprises a component selected from the group consisting of phosphorus, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, osteopontin and combinations thereof In another embodiment, this nutritional composition further comprises at least one antioxidant. In another embodiment, this nutritional composition further comprises at least one phytonutrient. In another embodiment, the patient is a child.
In another embodiment, this invention provides for a method for preserving the fractional rate of mixed muscle protein synthesis under conditions of inflammation, the method comprising: administering to a patient in need of same a nutritional composition comprising exogenous vitamin K2. In another embodiment, this nutritional composition further comprises a component selected from the group consisting of phosphorus, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, osteopontin and combinations thereof In another embodiment, this nutritional composition further comprises at least one antioxidant. In another embodiment, this nutritional composition further comprises at least one phytonutrient. In another embodiment, the patient is a child.
It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications can be made without departing from the spirit and scope of the present subject matter and without diminishing its intended advantages. It is therefore intended that such changes and modifications be covered by the appended claims.

Claims (17)

The invention is claimed as follows:
1. A method of modulating the effects of inflammation, the method comprising administering a nutritional composition comprising an effective amount of exogenous MK-7 to a patient having cystic fibrosis.
2. The method of claim 1, wherein the effective amount of exogenous MK-7 is from about 1 μg to about 100 μg per day.
3. The method of claim 1, wherein the effective amount of exogenous MK-7 is from about 20 μg to about 90 μg per day.
4. The method of claim 1, wherein the effective amount of exogenous MK-7 is from about 50 μg to about 80 μg per day.
5. The method of claim 1, wherein the nutritional composition is in an administrable form selected from the group consisting of pharmaceutical formulations, nutritional formulations, tube-feed formulations, dietary supplements, functional foods and beverage products.
6. The method of claim 1, the nutritional composition further comprising at least one component selected from the group consisting of prebiotic, probiotics, symbiotic, amino acid, protein, nucleotides, a fish oil, non-marine omega-3 fatty acid containing dietary fat source, phytonutrients, antioxidant, and combinations thereof.
7. The nutritional composition of claim 6, wherein the amino acid is selected from the group consisting of proline, hydroxyproline, hydroxytyrosine, hydroxylysine and hydroxyserine and combinations thereof.
8. The method of claim 1, wherein the modulation of the effects of inflammation is a reducing of the effects of inflammation.
9. The method of claim 1, wherein the modulation of the effects of inflammation is a preventing of the effects of inflammation.
10. The method of claim 1, wherein the modulation of the effects of inflammation is decreasing a rise of plasma TNF-α under conditions of inflammation.
11. The method of claim 1, wherein the modulation of the effects of inflammation is blunting a drop in phosphorylation for IKKα/β and NFκB p65 induction under conditions of inflammation.
12. The method of claim 1, wherein the modulation of the effects of inflammation is abrogating a decrease in 4E-BP1(Thr-37) and ribosomal protein S6 phosphorylation under conditions of inflammation.
13. The method of claim 1, wherein the modulation of the effects of inflammation is preserving the fractional rate of mixed muscle protein synthesis under conditions of inflammation.
14. The method of claim 1, comprising the steps of:
determining a genetic predisposition of the patient to determine the likely efficacy of treatment with exogenous MK-7; and
if determined to be efficacious, administering to the patient the nutritional composition comprising the effective amount of the exogenous vitamin MK-7 and a component selected from the group consisting of phosphorus, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, osteopontin and combinations thereof.
15. The method of claim 14 wherein the determining of the genetic predisposition comprises determining the genotype.
16. The method of claim 14 wherein the genetic predisposition is used to determine the dosage of the exogenous MK-7.
17. The method of claim 1, wherein the patient is a child.
US15/099,257 2009-09-14 2016-04-14 Nutritional compositions for modulating inflammation including exogenous vitamin K2 Active 2030-10-13 US9687456B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US15/099,257 US9687456B2 (en) 2009-09-14 2016-04-14 Nutritional compositions for modulating inflammation including exogenous vitamin K2
US15/389,945 US20170105948A1 (en) 2009-09-14 2016-12-23 Nutritional compositions for modulating inflammation including exogenous vitamin k2

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US24208709P 2009-09-14 2009-09-14
US25084709P 2009-10-12 2009-10-12
US34794510P 2010-05-25 2010-05-25
US37184610P 2010-08-09 2010-08-09
PCT/US2010/047468 WO2011031602A1 (en) 2009-09-14 2010-09-01 Nutritional compositions for modulating inflammation including exogenous vitamin k2
US201213395060A 2012-04-24 2012-04-24
US15/099,257 US9687456B2 (en) 2009-09-14 2016-04-14 Nutritional compositions for modulating inflammation including exogenous vitamin K2

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US13/395,060 Division US20120208893A1 (en) 2009-09-14 2010-09-01 Nutritional compositions for modulating inflammation including exogenous vitamin k2
PCT/US2010/047468 Division WO2011031602A1 (en) 2009-09-14 2010-09-01 Nutritional compositions for modulating inflammation including exogenous vitamin k2

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/389,945 Division US20170105948A1 (en) 2009-09-14 2016-12-23 Nutritional compositions for modulating inflammation including exogenous vitamin k2

Publications (2)

Publication Number Publication Date
US20160220511A1 US20160220511A1 (en) 2016-08-04
US9687456B2 true US9687456B2 (en) 2017-06-27

Family

ID=43098924

Family Applications (5)

Application Number Title Priority Date Filing Date
US13/395,054 Abandoned US20130052274A1 (en) 2009-09-14 2010-09-01 Nutritional compositions including exogenous vitamin k2
US13/395,060 Abandoned US20120208893A1 (en) 2009-09-14 2010-09-01 Nutritional compositions for modulating inflammation including exogenous vitamin k2
US13/963,244 Abandoned US20130323361A1 (en) 2009-09-14 2013-08-09 Nutritional compositions including exogenous vitamin k2
US15/099,257 Active 2030-10-13 US9687456B2 (en) 2009-09-14 2016-04-14 Nutritional compositions for modulating inflammation including exogenous vitamin K2
US15/389,945 Abandoned US20170105948A1 (en) 2009-09-14 2016-12-23 Nutritional compositions for modulating inflammation including exogenous vitamin k2

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US13/395,054 Abandoned US20130052274A1 (en) 2009-09-14 2010-09-01 Nutritional compositions including exogenous vitamin k2
US13/395,060 Abandoned US20120208893A1 (en) 2009-09-14 2010-09-01 Nutritional compositions for modulating inflammation including exogenous vitamin k2
US13/963,244 Abandoned US20130323361A1 (en) 2009-09-14 2013-08-09 Nutritional compositions including exogenous vitamin k2

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/389,945 Abandoned US20170105948A1 (en) 2009-09-14 2016-12-23 Nutritional compositions for modulating inflammation including exogenous vitamin k2

Country Status (16)

Country Link
US (5) US20130052274A1 (en)
EP (2) EP2477510B1 (en)
JP (3) JP2013504571A (en)
CN (2) CN102781258A (en)
AU (2) AU2010292439A1 (en)
BR (1) BR112012005783A2 (en)
CA (2) CA2773940A1 (en)
DK (1) DK2477510T3 (en)
ES (1) ES2669004T3 (en)
IN (2) IN2012DN02184A (en)
MX (2) MX2012003081A (en)
RU (2) RU2012114832A (en)
SG (2) SG179064A1 (en)
TR (1) TR201808128T4 (en)
WO (2) WO2011031601A2 (en)
ZA (2) ZA201202712B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021167562A1 (en) * 2020-02-21 2021-08-26 Montero Gida Sanayi Ve Ticaret Anonim Sirketi Nutritional compositions for cancer patients undergoing chemotherapy and/or radiotherapy and/or pre-post surgery

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130028864A1 (en) * 1998-04-08 2013-01-31 Theta Biomedical Consulting & Development Co., Inc. Anti-inflammatory compositions for treating brain inflammation
JP2013504571A (en) * 2009-09-14 2013-02-07 ネステク ソシエテ アノニム Nutritional composition containing exogenous vitamin K2
WO2012143405A1 (en) * 2011-04-18 2012-10-26 Nestec S.A. Nutritional compositions having alpha-hica and alpha-ketoglutarate
US8183227B1 (en) 2011-07-07 2012-05-22 Chemo S. A. France Compositions, kits and methods for nutrition supplementation
US8168611B1 (en) 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation
CN102772401A (en) * 2011-10-02 2012-11-14 南京大学 Novel osteoporosis resistant use of carnosol
WO2013144267A2 (en) * 2012-03-29 2013-10-03 Nestec S.A. Improvement of musculoskeletal health by nutrition and exercise
WO2013144268A1 (en) * 2012-03-29 2013-10-03 Nestec S.A. Nutrition and exercise against drug-associated malnutrition in children
JP6368306B2 (en) * 2012-07-31 2018-08-01 ネステク ソシエテ アノニム Nutritional composition for promoting musculoskeletal health in patients with inflammatory bowel disease (IBD)
US20150250839A1 (en) * 2012-09-11 2015-09-10 Dakota Star Capital Llc Nutritional supplement containing iron
CN103142640A (en) * 2013-04-01 2013-06-12 李拖平 Health care product containing vitamin K2 and having functions of preventing and treating brittle-bone disease
WO2017114686A1 (en) * 2015-12-30 2017-07-06 Nestec S.A. Method for determining fat free body mass
CN105815791B (en) * 2016-03-24 2018-12-18 刘超 It is a kind of with muscle-increasing function and to eliminate the composition of adverse reaction
MX2018014933A (en) * 2016-06-02 2019-04-09 Ana Pharmaceuticals Inc Methods and compositions for treatment of hypercalciuria and nephrolithiasis.
US20220175851A1 (en) * 2019-03-13 2022-06-09 The Regents Of The University California Compositions, methods for regulating uterine, placental growth
CN110122866A (en) * 2019-05-31 2019-08-16 广东双骏生物科技有限公司 A kind of the special medicine purposes food and preparation method of chronic kidney disease angiosteosis
WO2023275183A1 (en) 2021-06-29 2023-01-05 Kappa Bioscience As Composition comprising vitamin k, vitamin d, xanthophyll and epa and/or dha
CN115989871A (en) * 2021-10-20 2023-04-21 安琪纽特股份有限公司 Composition for promoting growth and development as well as preparation method and application thereof
CN115590198B (en) * 2022-09-26 2024-06-18 黑龙江飞鹤乳业有限公司 Use of nucleotide, nutritional composition, food and use thereof

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0689835A2 (en) 1994-06-30 1996-01-03 Ajinomoto Co., Inc. Composition comprising a mixture of amino acids and at least one N-3 fatty acid
WO1997039746A1 (en) 1996-04-22 1997-10-30 Advanced Polymer Systems, Inc. Method of and composition for treating disorders of the skin using vitamin k
EP1153548A1 (en) 2000-05-12 2001-11-14 Unilever N.V. Vitamin k2 containing food product
GB2370503A (en) 2000-12-27 2002-07-03 Novartis Nutrition Ag Compositions comprising vitamin K
US6566064B1 (en) 1999-05-18 2003-05-20 Nipro Corporation Method for anticipating sensitivity to medicine for osteoporosis
JP2004155658A (en) 2002-11-01 2004-06-03 Kyowa Hakko Kogyo Co Ltd TNF-alpha PRODUCTION INHIBITOR
WO2005030190A1 (en) 2003-09-26 2005-04-07 Natural Asa Natural menaquinone 7 compositions
WO2006126541A1 (en) 2005-05-27 2006-11-30 Shionogi & Co., Ltd. Pharmaceutical composition comprising vitamin k
WO2008006607A2 (en) 2006-07-14 2008-01-17 Nattopharma Asa Pharmaceutical and nutraceutical products comprising vitamin k2
WO2009095240A1 (en) 2008-01-28 2009-08-06 Friesland Brands B.V. Methods and compositions for the treatment of bone conditions
WO2009105234A2 (en) * 2008-02-19 2009-08-27 Combinatorx, Incorporated Methods and compositions for the treatment of disorders associated with defects of the cystic fibrosis transmembrane conductance regulator gene or protein
US20090234022A1 (en) 2008-03-13 2009-09-17 Hana Biosciences, Inc. Formulations of vitamin K analogs for topical use
US8138162B2 (en) 2004-06-04 2012-03-20 Horizon Science Pty Ltd. Natural sweetener

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US371846A (en) 1887-10-18 Tennis-racket
US250847A (en) 1881-12-13 Vehicle-top
US347945A (en) 1886-08-24 vavtu
US242087A (en) 1881-05-24 Machine for making laps on belting
JPH07119191B2 (en) * 1990-08-16 1995-12-20 株式会社日本触媒 Method for stabilizing menadione bisulfite and composition of menadione bisulfite
US5132113A (en) * 1990-10-26 1992-07-21 Maurizio Luca Nutritional composition containing essential amino acids
JP3459932B2 (en) * 1996-07-23 2003-10-27 株式会社ホーネンコーポレーション Anti-osteoporosis composition
NZ507335A (en) * 2000-10-05 2004-10-29 New Zealand Dairy Board Bone health compositions derived from milk comprising an acidic protein fraction but that does not contain CGMP
JP4131443B2 (en) * 2001-08-27 2008-08-13 株式会社Ｊ−オイルミルズ Anti-osteoporosis composition
WO2005107731A1 (en) * 2004-05-12 2005-11-17 Eisai R & D Management Co., Ltd. Remedies containing vitamin k2 as the active ingredient
US20060223730A1 (en) * 2005-04-04 2006-10-05 Hl Distribution Company Calcium supplements
JP2006325487A (en) * 2005-05-26 2006-12-07 Pola Chem Ind Inc Nutrient-supplementary solid food
BE1016895A6 (en) * 2005-12-16 2007-09-04 Psaltopoulos Emmanuel Calcium composition, useful to prevent/treat osteoporosis and articular cartilage calcification, comprises optionally elementary calcium in the form e.g. of calcium carbonate or calcium citrate, and vitamins e.g. vitamin-D3, vitamin-K3
US20080171319A1 (en) * 2006-02-06 2008-07-17 Mickey Urdea Osteoporosis associated markers and methods of use thereof
US9011930B2 (en) * 2006-05-01 2015-04-21 Zycal Bioceuticals Healthcare Company, Inc. Nutritional supplement and use thereof
FR2906816B1 (en) * 2006-10-04 2012-04-06 Gervais Danone Sa VARIANTS OF LACTIC ACID BACTERIA USEFUL IN PRODUCING VITAMIN K2 AND THEIR APPLICATIONS TO THE PREPARATION OF FOOD PRODUCTS
US20080220094A1 (en) * 2006-11-01 2008-09-11 Wyeth Compositions and methods for the treatment and/or prevention of osteoporosis
BRPI0812686A2 (en) * 2007-07-24 2011-10-18 Viridis Biopharma Pvt Ltd vitamin K analogues and derivatives for the treatment of human disease conditions and disorders
JP2013504571A (en) * 2009-09-14 2013-02-07 ネステク ソシエテ アノニム Nutritional composition containing exogenous vitamin K2

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0689835A2 (en) 1994-06-30 1996-01-03 Ajinomoto Co., Inc. Composition comprising a mixture of amino acids and at least one N-3 fatty acid
WO1997039746A1 (en) 1996-04-22 1997-10-30 Advanced Polymer Systems, Inc. Method of and composition for treating disorders of the skin using vitamin k
US6566064B1 (en) 1999-05-18 2003-05-20 Nipro Corporation Method for anticipating sensitivity to medicine for osteoporosis
EP1153548A1 (en) 2000-05-12 2001-11-14 Unilever N.V. Vitamin k2 containing food product
GB2370503A (en) 2000-12-27 2002-07-03 Novartis Nutrition Ag Compositions comprising vitamin K
JP2004155658A (en) 2002-11-01 2004-06-03 Kyowa Hakko Kogyo Co Ltd TNF-alpha PRODUCTION INHIBITOR
WO2005030190A1 (en) 2003-09-26 2005-04-07 Natural Asa Natural menaquinone 7 compositions
US8138162B2 (en) 2004-06-04 2012-03-20 Horizon Science Pty Ltd. Natural sweetener
WO2006126541A1 (en) 2005-05-27 2006-11-30 Shionogi & Co., Ltd. Pharmaceutical composition comprising vitamin k
US20090137614A1 (en) 2005-05-27 2009-05-28 Shionogi & Co., Ltd. Pharmaceutical combination comprising vitamin k
WO2008006607A2 (en) 2006-07-14 2008-01-17 Nattopharma Asa Pharmaceutical and nutraceutical products comprising vitamin k2
WO2009095240A1 (en) 2008-01-28 2009-08-06 Friesland Brands B.V. Methods and compositions for the treatment of bone conditions
WO2009105234A2 (en) * 2008-02-19 2009-08-27 Combinatorx, Incorporated Methods and compositions for the treatment of disorders associated with defects of the cystic fibrosis transmembrane conductance regulator gene or protein
US20090234022A1 (en) 2008-03-13 2009-09-17 Hana Biosciences, Inc. Formulations of vitamin K analogs for topical use

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
Cooney, Robert et al. "TNF-binding protein ameliorates inhibition of skeletal muscle protein synthesis during sepsis" The Pennsylvania Sate University College of Medicine, Hershey, Pennsylvania; 1999, pp. E611-E619.
English Translation of Japanese Office Action for Patent Application No. P2015-196933 mailed Apr. 11, 2017.
Iwamoto, Jun. " Effect of Vitamin K and Growth Hormone on the Long Bones in Hypophysectomized Young Rats". J. Bone Miner. Metab. (2007) 25:46-53.
Japanese Office Action for Application No. P2015-196933, Dispatch No. 372656, Dispatch Date Aug. 23, 2016, 6 pages.
Japanese Office Action for Patent Application No. P2015-196933 mailed Apr. 11, 2017.
JP2004155658 Shunichi et al. 2004 English translation.
Li et al., "NF-κB mediates the protein loss induced by TNF-α in differentiated skeletal muscle myotubes" Am J Physiol Regulatory Integrative Comp Physiol, 2000, vol. 279, pp. R1165-R1170.
Sato, Toshiro et al. "Comparison of Metabolism of Menaquinone-4 and Menaquinone-7 in Rats" J-Oil Mills, Inc., Vitamins (Japan), 81 (8), 377-381 (2007).
Taminiau Review Article: the clinical importance of growth in children with inflammatory bowel disease: is it important to the gastroenterologist? Alimentary Pharmacology and Therapeutics, (Dec. 2007), vol. 26, No. Suppl. 2, pp. 53-56.
Written Opinion and International Search Report issued Dec. 2, 2010 for corresponding Intl. Appln. No. PCT/US2010/047468.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021167562A1 (en) * 2020-02-21 2021-08-26 Montero Gida Sanayi Ve Ticaret Anonim Sirketi Nutritional compositions for cancer patients undergoing chemotherapy and/or radiotherapy and/or pre-post surgery

Also Published As

Publication number Publication date
IN2012DN02184A (en) 2015-05-22
JP2013504572A (en) 2013-02-07
MX2012003081A (en) 2012-04-19
SG179065A1 (en) 2012-04-27
CN102596190A (en) 2012-07-18
US20160220511A1 (en) 2016-08-04
US20130052274A1 (en) 2013-02-28
EP2477618A2 (en) 2012-07-25
DK2477510T3 (en) 2018-05-28
JP2016041705A (en) 2016-03-31
RU2012114786A (en) 2013-10-27
AU2010292440A1 (en) 2012-04-12
RU2012114832A (en) 2013-10-27
MX2012003080A (en) 2012-04-19
CA2773957C (en) 2018-01-09
JP2013504571A (en) 2013-02-07
US20130323361A1 (en) 2013-12-05
TR201808128T4 (en) 2018-07-23
EP2477510A1 (en) 2012-07-25
BR112012005783A2 (en) 2017-05-30
AU2010292439A1 (en) 2012-04-12
EP2477510B1 (en) 2018-03-07
ES2669004T3 (en) 2018-05-23
US20120208893A1 (en) 2012-08-16
CA2773957A1 (en) 2011-03-17
SG179064A1 (en) 2012-04-27
AU2010292440B2 (en) 2015-06-18
CN102781258A (en) 2012-11-14
WO2011031601A2 (en) 2011-03-17
CA2773940A1 (en) 2011-03-17
WO2011031602A1 (en) 2011-03-17
US20170105948A1 (en) 2017-04-20
IN2012DN02245A (en) 2015-05-22
ZA201202712B (en) 2014-10-29
ZA201202711B (en) 2014-10-29
WO2011031601A3 (en) 2011-06-03

Similar Documents

Publication Publication Date Title
US9687456B2 (en) Nutritional compositions for modulating inflammation including exogenous vitamin K2
AU2012244748B2 (en) Nutritional compositions comprising alpha-hydroxyisocaproic acid
US20140294788A1 (en) Methods for enhancing muscle protein synthesis following concurrent training
US20120308525A1 (en) Nutritional compositions including a high protein component and exogenous nucleotides
Chmiel et al. Vitamins as regulators of calcium-containing kidney stones—new perspectives on the role of the gut microbiome
US20120270830A1 (en) Nutritional compositions including theanine and exogenous nucleotides
WO2015040533A1 (en) Methods for enhancing muscle protein synthesis during energy deficit

Legal Events

Date Code Title Description
AS Assignment

Owner name: NESTEC S.A., SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BOLSTER, DOUGLAS RICHARD;ROUGHEAD, ZAMZAM KABIRY;REEL/FRAME:040681/0689

Effective date: 20100921

STCF Information on status: patent grant

Free format text: PATENTED CASE

AS Assignment

Owner name: SOCIETE DES PRODUITS NESTLE S.A., SWITZERLAND

Free format text: MERGER;ASSIGNOR:NESTEC S.A.;REEL/FRAME:049391/0756

Effective date: 20190528

AS Assignment

Owner name: SOCIETE DES PRODUITS NESTLE S.A., SWITZERLAND

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ENGLISH TRANSLATION TO SHOW THE FULL AND CORRECT NEW NAME IN SECTION 51. PREVIOUSLY RECORDED AT REEL: 049391 FRAME: 0756. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER;ASSIGNOR:NESTEC S.A.;REEL/FRAME:049853/0398

Effective date: 20190528

AS Assignment

Owner name: SOCIETE DES PRODUITS NESTLE S.A., SWITZERLAND

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912;ASSIGNOR:NESTEC S.A.;REEL/FRAME:054082/0165

Effective date: 20190528

Owner name: SOCIETE DES PRODUITS NESTLE S.A., SWITZERLAND

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912;ASSIGNOR:NESTEC S.A.;REEL/FRAME:054082/0001

Effective date: 20190528

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4